A comparative study of the diffusion of antihypertensive and antidepressant medications in Germany in Japan by Cui, Ling, 1978-
A Comparative Study of the Diffusion of Antihypertensive
and Antidepressant Medications in Germany and Japan
by
Ling Cui
Master of Science in Aeronautics and Astronautics, MIT, 2004
Bachelor of Engineering, Beijing University of Aeronautics and Astronautics, 2001
Submitted to the Engineering Systems Division
in Partial Fulfillment of the Requirements for the Degree of
Master of Science in Technology and Policy
at the S
Massachusetts Institute of Technology
JUN 0 1 2005
June 2005 S
©2005 Massachusetts Institute of Technology
All rights reserved.
Author ........ ................... ................... ...................
Tec-hrology and Policy Program, Engineering Systems Division
May 13, 2005
Certified by ...................................................
Ernst R. Berndt
Louis E Seley Professor of Applied Economics, Sloan School of Management
Thesis Supervisor
Accepted by.......................epted  .... ....  I. ........................................
Dava J. Newman
Professor of Aeronautics and Astronautics and Engineering Systems
Director, Technology and Policy ProgramARHI' VES t

A Comparative Study of the Diffusion of the Antihypertensive and
Antidepressant Medications in Germany and Japan
by
Ling Cui
Submitted to the Engineering Systems Division on May 13, 2005
in Partial Fulfillment of the Requirements for
the Degree of Master of Science in Technology and Policy
Abstract
This thesis analyzes and compares the diffusion of antihypertensive and antidepressant
medications in Germany and Japan during the time period of 1992 and 2003. The
antihypertensive medications are classified as new, middle and old generations and the
antidepressants are classified as new and old generations in this study. The demographic,
economic, price, promotional, regulatory, and cultural factors that contributed to the sales
level, number of compounds available in the market, and launch time of these
medications are also examined using quantitative and qualitative methods at therapeutic
class, generation, as well as product levels.
The qualitative analysis includes discussions on the general health care systems, health
care polices, and country-specific hypertension- and depression-related cultural
backgrounds. Econometric tools (descriptive statistics and linear regression models) are
used as means of quantitative analysis. The diffusion of different generations of
medications is examined. The degree of the use of branded vs. generic medications are
also compared. Finally, Chow-tests are conducted for cross-country and cross-
therapeutic-class comparisons.
This study finds that there are significant branded-v-generic, cross-generation, cross-
class, cross-country differences in the diffusion of the selected therapeutic classes in the
two countries. The factors examined contributed to the diffusion to various extents.
Among which, the cultural factor played an important role in the adoption and sales of
new medications of both therapeutic classes in both countries, especially the
antidepressants in Japan. The promotional factors appear not to be very significant in the
sales volumes, partially due to the regulatory settings of the two national-based health
care systems.
Thesis Supervisor: Ernst R. Berndt
Title: Louis E Seley Professor of Applied Economics, Sloan School of Management
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Chapter 1 Introduction
1.1 Motivation and objective
In all developed countries, pharmaceuticals are heavily regulated products. However, the
regulation of pharmaceuticals varies across countries and therapeutic classes due to
variations in regulatory systems, historic traditions, and cultures. The different
regulations affect not only the pricing of medications, but also the economic behaviors of
pharmaceutical manufacturers in marketing and promotions, and hence the diffusion (the
level and the pattern of sales) of pharmaceuticals. It is therefore interesting to investigate
the direct and indirect factors affecting pharmaceutical diffusion. This thesis is aimed to
compare the diffusion of two selected medications in two countries and to examine the
various factors that contributed to the diffusion using both quantitative and qualitative
approaches.
Two therapeutic classes are chosen in the analysis - antihypertensives and
antidepressants. The reasons for choosing these therapeutic classes are: antihypertensives
are a "standard" class, where there is little discrepancy in prescription with regard to
syndrome and dosage. Hence there is less noise added for medical practice reasons; the
diffusion of antidepressants has demonstrated a distinct pattern in Japan, in part resulting
from public and medical professionals' perceptions and manufacturers' advertising
strategies.
The countries in this analysis are Germany and Japan. The reason for choosing these
countries is that Japan's health care system has its root in the Bismarck's Germany.
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Germany has a health care system that covers everything except long-term or permanent
care. In 1961, the Japanese government achieved its goal of universal coverage. Hence
they are both national-based health care systems [1]. However, the sales of
pharmaceuticals have exhibited distinctive differences over time due to other factors such
as the particular health care policies and regulations and practice of medicine. The
regulatory, economic, and cultural factors contributing to the diffusions will also be
analyzed.
The time period in this thesis is between the first quarter of 1992 and the last quarter of
2003. Quantitative (descriptive statistics and econometric models) and qualitative
methods are used to analyze and compare the different patterns of diffusion.
There have been a number of studies that have analyzed diffusion of pharmaceuticals
using econometric methods. For example, Ramarao Desiraju et al. studied the diffusion
of new pharmaceutical drugs in developing and developed nations [2], and John Vernon
examined the concentration, promotion and market share stability in the pharmaceutical
industry [3]. Few have taken promotion efforts and/or regulatory effects on the sales of
pharmaceuticals. These include Ernst Berndt et al. 1997 on the role of marketing,
product quality and price competition in the growth and composition of the U.S. antiulcer
drug industry [4] and Fabio Pammolli, et al 2002 on the competition after patent expiry in
pharmaceuticals. There are also literatures on the economics of antihypertensive and
antidepressanat medications, such as Ernst Berndt et al. 1992 on the price indexes for
antihypertensive drugs [5], and Ernst Berndt et al. 1996 on tracking the effects on price
indexes for antidepressant drugs [6].
However, this thesis has a different focus from these previous studies. Firstly, this thesis
includes cross-therapeutic-class and cross-country comparisons of the diffusion of
particular pharmaceuticals that have not been conducted before; secondly, a broad range
of factors that contribute to the diffusion of these pharmaceuticals is analyzed, including
demographic, economic, promotional, price, as well as regulatory factors.
12
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1.2 The German and the Japanese health care systems
As mentioned in section 1.1, both the German and the Japanese health care systems are
national-based. In this section these two health care systems (especially the financing of
the health care) are compared. Then the regulations on pricing and co-payment of
pharmaceuticals in Germany and Japan are discussed. After that, the total sales of
pharmaceuticals in these two countries are illustrated. Finally, some demographic
features (age and gender structures) are presented.
The two health care systems
The German health care system is based on a compulsory insurance scheme [1]. The
insurance funds are highly decentralized (more than 1,000 before 1995 and -380 in 2004)
and they cover approximately 90% of the population. Eight percent of the population is
covered by private insurance and the rest 2% are mainly government officials that are
covered by the Government administers health care plans [7]. German physicians are
paid fee-for-service, which gives them an incentive to increase the number of patients
they see. However, the reimbursement policy sets a cap on the total amount of all
doctors' compensations, which results in a strong competition amongst physicians in their
efforts to expand their volume of treatment [1]. In Germany, the patients have free
choice of physician. As in the U.S., a general practitioner may refer the patient to a
specialist if needed.
Unlike the decentralized German health insurance funds, the Japanese health care
insurance funds are highly centralized: the basic categories include Employee Health
Insurance (covering -56% of the population), National Health Insurance and Health
Service for the Elderly (covering 36% of the population), and a group of minor
government insurance plans for government employees, seamen and private teachers
(covering about 8% of the population) [7]. The physicians in Japan are also paid on a
fee-for-service basis, among which there is no price competition. These provide the
doctors an incentive to treat as many patients as possible, as well as expansion of the
volume of drugs prescribed. Unlike in the rest of the world, the Japanese doctors do not
13
specialize to the extent observed elsewhere. Patients can choose hospitals and
physicians.
Regulations on pricing and co-payment of pharmaceuticals
The German health care regulatory body is the Federal Institute for Drugs and Medical
Devices (Bundesinstitut fur Arzneimittel und Medizinprodukte, or BfArm), which
handles product approval and health/safety-related matters. The Gemeinsamer
Bundesausschuss (Joint Federal Committee) determine the prices of pharmaceuticals.
The pricing of pharmaceuticals in Germany is based on a reference price system,
introduced in the 1989 Health Reform Act [1]. Under this system the reimbursement
levels of medicines are fixed at the reference price and the patient will pay for the
difference between the actual price and the reference price. An insured person will pay
for the lesser of 10% of retail price or ten Euros [7].
The Ministry of Health, Labor and Welfare (MHLW, or Kosei-roudou-sho in Japanese)
manages all health regulatory matters in Japan, a merger of the Ministry of Labor and the
Ministry of Health and Welfare in 2001 [7]. The prices of all medicines are regulated by
the MHLW based on the innovativeness, cost of R&D, and reasonable profit margins of
the product. Almost all of the listed drugs are fully reimbursed minus the patient co-pay
(the co-payment rate ranges from 0% to 30% depending on a patient's social and
occupational status).
The overall markets of pharmaceuticals
Figures 1.1 and 1.2 illustrate the overall spending and per-capita spending on
pharmaceuticals in Germany and Japan over time (1992 - 2003). The sales are in
Purchasing Power Parity adjusted U.S. dollars. The figures show that Japan had higher
per-capita U.S. dollar sales of pharmaceuticals than Germany (except for 1992), and the
difference was enlarged over time.
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In terms of the use of generics, Germany has a well-developed generics market, aimed to
reduce health care costs. However, in Japan the generics have relatively low penetration
rates [7]. This feature will be confirmed to be true for the antihypertensive and
antidepressant medications in the econometric analysis in chapters 3 and 4.
Demographic features
Figures 1.3, 1.4 and 1.5 present the levels and changes of the age and gender structures in
Germany and Japan over time. The age structure is decomposed to 0-14 years old, 15-64
years old, and 65 years old and over; the gender structure is presented by an illustration
of the percentages of females over the total population.
As shown in Figures 1.3 and 1.4, both countries had increased 65-years-and-over
percentage over time, and decreased percentages for the other two age groups. Japan had
a higher percentage of people over 65 years old at the end of time period than Germany
(18.4% vs. 17.3%). In addition, the gender structures show that there is a higher
percentage of females in Germany than in Japan (this might be partially resulted from
World War II, when numerous German males died.)
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1.3 Thesis organization
This thesis contains five major sections. Chapter 1 is the introduction, and chapter 2
discusses the data sources, regression models and definitions of the corresponding
variables. Chapter 3 and chapter 4 provide detailed discussions about the sales of
antihypertensives and antidepressants in Germany and Japan, as well as the factors that
contributed to the sales of these medications. Chapter 5 compares the cross-country and
cross-therapeutic-class differences of the medications. At the end of chapter 5 a
conclusion of the thesis is made.
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Chapter 2 Data and Regression Models
2.1 Overview of the data
The original data directly obtained from databases for the descriptive analysis and
econometric analysis in this study includes: 1) quarterly sales and promotion of the
antihypertensive and antidepressant medications in Germany and Japan, 2) annual
demographic data (age structure), 3) annual macroeconomic data (gross domestic product
(GDP) per capita), and 4) annual number of physicians per capita as a health care system
indicator. All of the data cover the time period from the first quarter of 1992 to the fourth
quarter of 2003.
The sales and promotion data was obtained from the IMS International database. IMS is
a Philadelphia-based firm, which independently collects data on the sales and marketing
of pharmaceuticals. The IMS quarterly sales data is collected at presentational form (for
example, bottles of 50 tablets of 100-mg pills). The sales data used in this thesis is in
patient days, which were calculated by IMS from the total grams sold divided by
recommended daily dosage of that medication. In the analyses, the data is further
aggregated at product-country-quarter and higher levels. The sales data is also reported
in monetary values - national currencies and U.S. dollars converted from exchange rates.
Here the U.S. dollar values are used in the analyses for the German and Japanese
markets, each deflated by Producer Price Index (PPI). The prices per patient day of the
drugs were then calculated from the PPI-adjusted dollar values divided by number of
patient days at the appropriate levels. (The detailed definitions of variables will be
introduced in section 2.2.)
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Table 2. 1 Number of molecules in the sample
Country Antihypertensives Antidepressants
Germany 56 35
Japan 62 20
Table 2. 2 Number of products in the sample
Country Antihypertensives Antidepressants
Germany 18004 9425
Japan 6717 1465
The products in the sample cover 56 antihypertensive molecules and 35 antidepressant
molecules in Germany, 62 antihypertensive molecules and 20 antidepressant molecules in
Japan. The number of molecules is shown in Table 2.1 and the number of products is
shown in Table 2.2.
IMS collects three kinds of promotion data and reports the data at aggregated local-
product level: detailing, journal advertising and advertisement through mail. Detailing
means the visits that the sales representatives of pharmaceutical companies pay to
physicians. In this research, the number of detailing counts will be used to denote
promotional efforts for three reasons: 1) detailing is the most effective (and expensive)
means of promotion; 2) the journal and mail advertising data is unavailable for the
Japanese market; 3) detailing tends to be a very short visit (usually a few minutes), so it is
reasonable to use the number of detailing visits to measure the promotion intensity
without considering the variance in the length of each visit.
For most countries in the IMS International database, IMS reports the sales of
pharmaceutical products in the retail sector because the retail sales count for the majority
of the pharmaceutical market (for example, Germany). However, the data for Japan
includes the sales in the retail sector and those in hospitals. This is because in Japan
physicians are allowed to dispense medications. As a result, the hospital sales are at a
20
similar level and of a similar pattern to the retail sales. Hence in this study the retail
sales data is combined with the hospital sales data for Japan to represent the Japanese
market.
In addition, the IMS database also provides time-invariant information such as each
product's manufacturer, launch time, and license type. In the regression models, the
license type is used as dummy variables. The IMS data has 4 license types: Originator
("O"), Licensee ("L"), Other Brand ("B"), Generics ("G") and "NA". The products with
license "O", "L" or "B" are grouped as branded drugs; and products with license "G" or
"NA" are grouped as generic drugs. Table 2.3 lists the number of branded and generic
antihypertensive and antidepressant drugs in Germany and Japan. (Note that in both
countries there are more branded products than generic products.)
The demographic, economic2, and health care system data are obtained from the 2004
Organization of Economic Cooperation and Development (OECD) Health Database. The
data in the OECD Health Database is obtained from OECD member countries every year.
Table 2. 3 Number of branded and generic products in the sample
Country Branded/generic Antihypertensives Antidepressants
Branded 13466 6982
Germany
Generic 4538 2443
Branded 5965 1407
Japan
Generic 752 58
1 I have examined and compared the sales levels and patterns of the Japanese retail and
hospital sectors. They are consistent the statement here.
2 The GDP per capita was adopted as the economic factor. Percentage of post-secondary
education degree holders as well as the total health care spending per capita were tested
and they resembled similar effects to that of the GDP per capita variable.
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Lastly, the antihypertensive medications are classified into new, middle, and old
generations; and the antidepressant medications are classified into new and old
generations, based on the earliest launch time and the mechanism of action of each
compound. The necessary information for classification was obtained from the online
database PubMed [8], a service of the National Library of Medicine and the consultation
with Professor Ernst R. Berndt and Dr. Dirk M. Hentschel [9].
All of the original data are processed using SAS program. The final results of the
descriptive analysis (graphs) and the econometric analysis (regression models) are
presented in the forms of Microsoft Excel charts and SAS regression outputs
respectively.
2.2 Variables and regression models
There are eight linear regression models used throughout the study. In this section these
models are explained and the variables in the models are defined. The regression models
are aimed to examine numerically the relationship between the sales volume of
medications (in patient days per capita) and economic, health care system, promotion,
price, and competition factors at therapeutic class, generation, and product levels. The
first four equations are used for data that is separated by country and therapeutic class;
the last four equations are used for pooled data that includes both countries and
therapeutic classes. Firstly, a list and definitions of all the dependent variables and
explanatory variables used in the regression models is shown in Tables 2.4 and 2.5.
Table 2. 4 Dependent variables in regression models
Variable name Variable definition
tot_pd_capita Total patient days per capita at country-therapeutic class-time level
gen_pd_capita Number of patient days per capita of each generation at country-
therapeutic class-time level
share_new_pd Share of number of patient days of the new generation out of total at
country-therapeutic class-time level
prod_pd_capita Number of patient days per capita at country-therapeutic class-
product-time level
22
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Explanatory variables in regression models
Variable name Variable definition
income_lKcapita GDP per 1,000 population at country-time level
phys_lMpop Number of physicians per 1 million population at country-time level
pct0_14 Percentage of population that is between age 0 and 14
pct65p Percentage of population that is older than 65 years old
time Quarterly time trend variable, where first quarter in 1992 = 1
priceclass Average price of the drugs at country-therapeutic class-time level
price_gen Average price of the drugs at country- therapeutic class-generation-
time level
price_ratio Price ratio of the new generation and combined old & middle
generation. Prices are averaged at country- therapeutic class-
generation-time level
price_prod Price of individual products at country-therapeutic class-product-
time level
num compound Number of all compounds at country- therapeutic class-time level
num_new_compo Number of new compounds at country-therapeutic class-time level
und
share_num_newc num_new_compound divided by num_compound
mpnd
tot_detail_capita_ Lagged total detailing counts per capita at country-therapeutic class-
lagl time level, lagged by 1 quarter
tot_detail_capita_ Lagged total detailing counts per capita at country-therapeutic class-
lag4 time level, lagged by 4 cumulative quarters
gen_detail_capita Lagged detailing counts per capita at country-therapeutic class-
_lagI generation-time level, lagged by 1 quarter
gen_detail_capita Lagged detailing counts per capita at country-therapeutic class-
_lag4 generation-time level, lagged by 4 cumulative quarters
rel_detail_lagl Lagged ratio of new to old-and-middle detailing counts at country-
therapeutic class-time level, lagged by 1 quarter
rel_detail_lag4 Lagged ratio of new to old-and-middle detailing counts at country-
therapeutic class-time level, lagged by 4 cumulative quarters
prod_detail_lagl Lagged detailing counts per capita at country-therapeutic class-
product-time level, lagged by 1 quarter
prod_detail_lag4 Lagged detailing counts per capita at country-therapeutic class-
product-time level, lagged by 4 cumulative quarters
new Dummy variable for the new generation
middle Dummy variable for the middle generation
generic Dummy variable for generic drugs
timenew Variable "time" times dummy variable "new"
timemiddle Variable "time" times dummy variable "middle"
oldgen Dummy variable "old" times dummy variable "generic"
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Table 2. 5
The details of generations of medications are presented in sections 3.2 and 4.2. Also note
that tot_detail_capita_lagl and tot_detail_capita_lag4 are used separately in all of the
equations because they have high pair-wise correlation (>0.9). In addition, in the
logarithm form, pctO_14, pct65p, time trend variable and dummy variables are not
logged. Lastly, a 95% confidence level is used in all of the parameter estimates in the
regressions to assess statistical significance. The following is a list of the eight
regression models with the variables defined above.
Equation 1: class-level model
totpd_capita = fo + (3, . income_lKcapita + /32 phys_lMpop + /,3 pctO_14 + 4 '
pct65p + 35 time + P6 ' price_class + P7 ' price_ratio + 8 num_compound + 69 '
tot_detail_capita_lag
tot_pd_capita = /3o + , ' income_lKcapita + P2 phys_lMpop + ,3 . pctO_14 + /34 
pct65p + 65 time + ,6 price_class + ,7 . price_ratio + /38 num_compound + f,9 
tot_detail_capita_lag4
(where Po is the intercept term.)
Equation 2: generation-level model
gen_pd_capita = Po + 3, income_lKcapita + /32 phys_lMpop + ,3 pctO_14 + /34 
pct65p + /3 · time + 36 price_gen + /37 price_ratio + ,8 num_new_compound + /9 .
gen_detail_capita_lagl + o new + ,1 · timenew + 312 middle + /313 · timemiddle
gen_pd_capita = /3o + PI income_lKcapita + 32 phys_lMpop + /3 . pctO_14 + /34 
pct65p + 5 · time + /36 price_gen + /37 priceratio + /38 num_new_compound + /39 
gen_detail_capita_lag4 + 3lo new + ,l timenew + P,2 · middle + 313 · timemiddle
(Dummy variable old is omitted. For the antidepressants, there is no middle generation
or timemiddle.)
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Equation 3: share of new model
share_newpd = /o + , income_lKcapita + 62 .phys_lMpop + ,63 pctO_14 + ,34 
pct65p + ,/35 time + 6 price_ratio + 37 share_newcmpnd + 68 rel_detail_lagl
share_newpd = Po + , income_lKcapita + 2 phys_lMpop + 1,3 pctO_14 + ,4 .
pct65p + /35 time + 36 price_ratio + 37 share_newcmpnd + s8 rel_detail_lag4
Equation 4: product-level model
prodpd_capita = /o + B, income_lKcapita + 32 .phys_lMpop + 3.' pctO_14 + ,4 
pct65p + 5 · time + 36 priceprod + ,7 num_new_compound + 38 generic. + fi 
prod_detail_capita_lagl + ,o · new + ,, middle
prodpd_capita = Po + /3, income_lKcapita + 32 ·phys_lMpop + 3 pctO_14 + 4 '
pct65p + 5. time + 36 price-prod + 7 num_new_compound + 38 generic. + /39
prod_detail_capita_lag4 + 1, new + ,, middle
(Dummy variable old is omitted. For the antidepressants, there is no middle generation.)
Equation 5: pooled class-level model
totpd_capita = /o + , income_lKcapita + 32 phys_lMpop + 3, ' pctO_14 + ,4 '
pct65p + 5 · time + 6 price_class + P7 'price_ratio + 08 ' num_compound + ,9 '
tot_detail_capita_lagl + ,5 . Germany + I,, antihypertensives
totpd_capita = 3o + , income_lKcapita + 32 phys_lMpop + ,3 . pctO_14 + 4'
pct65p + 5 · time + 6 price_class + ,7 .price_ratio + 38 num_compound + 9
tot_detail_capita_lag4 + 1,o Germany + ,,1 antihypertensives
(Dummy variables Japan and antidepressants are omitted.)
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Equation 6: pooled generation-level model
genpd_capita = (o + B, income_lKcapita + 12 phys_IMpop + ,33 pctO_14 + 4 '
pct65p + ,5 time + 86 price_gen + 37 price_ratio + 38 num_new_compound + ( '
gen_detail_capita_lagl + sO new + P,, timenew + 3,2 ' middle + 13 ' timemiddle +
f4 ' Germany + f,5 ·antihypertensives
gen_pd_capita = Po + S, income_lKcapita + 32 phys_lMpop + (3 pctO_14 + 34
pct65p + ,5 time + 6 price_gen + ,7 price_ratio + 38 num_new_compound + , 39
gen_detail_capita_lag4 + o new + ,, ·timenew + ,12 ' middle + (83 timemiddle +
f, 4 Germany + ,5 antihypertensives
(Dummy variables Japan and antidepressants are omitted. For the antidepressants, there
is no middle generation or timemiddle.)
Equation 7: pooled share of new model
share_newpd = ( + , income_lKcapita + 2 phys_lMpop + ,3 pctO_14 + ,4 '
pct65p + ,65 time + 6 price_ratio + 37 share_newcmpnd + 38 rel_detail_lagl + 9'
Germany + Po antihypertensives
share_new_pd = Po + , income_lKcapita + 32 phys_lMpop + 3 pctO_14 + 4 '
pct65p + ,5 · time + 36 price_ratio + ,7 share_newcmpnd + 38 ' rel_detail_lag4 + ,9 
Germany + ,o antihypertensives
(Dummy variables Japan and antidepressants are omitted.)
Equation 8: product-level model
prod_pd_capita = Po + I, income_lKcapita + 32 phys_lMpop + 3' pctO_14 + 4,
pct65p + 35 time + 36 priceprod + (73 num_new_compound + 38 generic. + 9
prod_detail_capita_lagl + 3,0 new + I,,' middle + (,2 oldgen + 1,3 Germany + ,,4
antihypertensives
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prodpd_capita = 3o + 3, income_lKcapita + 32 phys_lMpop + 33 pctO_14 + P4 
pct65p + 35' time + 36 priceprod + 37, num_new_compound + [38 generic' + /39
prod_detail_capitalag4 + ,/30 new + /3, middle + /312' oldgen + /313 Germany + 314
antihypertensives
(Dummy variables Japan and antidepressants are omitted. For the antidepressants, there
is no middle generation.)
Equations 4-8 allow the intercepts to be different between the two countries and the two
therapeutic classes. However, in order to examine whether there is statistically
significant cross-country and cross-therapeutic-class differences in the estimated
parameters, Chow-tests are performed following the regression models in chapter 5. The
null hypothesis is that there is no cross-country or cross-therapeutic-class difference in
the parameter estimates. The Chow-statistic follows an F-distribution and is calculated
from the sum of squared residuals of semi-constrained and unconstrained models (SSRr
and SSRU). In this case, the unconstrained models are the regressions separated by
country and therapeutic class (Equations 1-4), and the semi-constrained models are the
pooled regression models (Equation 5-8). The Chow-test is conducted at the therapeutic
class level, generation level, and product level respectively.
Chow statistic = [(SSRr - SSRu)/ SSRu] x [(N-k)/q] - Fq, N-k
where SSRU = YSSRu, i, N is the total number of observations in the constrained model, k
is the total parameter estimates in the unconstrained models (including the intercept
terms), and cq is the difference of k and the number of estimated parameters in the
constrained model.
The Chow-statistic follows an F-distribution with q and N-k degrees of freedom. If the
Chow-statistic is greater than the critical value of Fq, N-k at 5% significance level, the Ho
hypothesis is rejected; otherwise the Ho hypothesis cannot be rejected.
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Chapter 3 Antihypertensives in Germany and Japan
In this chapter, a background discussion on hypertension and antihypertensive
medications is introduced. Following that, descriptive analyses of the antihypertensives
at the class, generation and product level are presented. Then econometric models are
used to quantify and compare the factors that contribute to the sales of antihypertensives
during 1992-2003 in Germany and Japan. A cross-generation comparison of the
medications is also included. Finally, a summary based on the descriptive and
econometric analyses is presented.
3.1 Symptoms and causes of hypertension
Hypertension, also called high blood pressure, is a condition occurring when the systolic
and diastolic pressures remain abnormally high (a reading of 140/90 mm Hg or higher)
[101. Most people with high blood pressure usually do not have noticeable symptoms.
Albeit over time, untreated high blood pressure can damage organs, such as the heart,
kidneys, or eyes by forcing the heart and blood vessels to overwork. This may lead to
chest pain (angina), heart attack, stroke, kidney (renal) failure, peripheral vascular
disease, eye damage (retinopathy), or abnormal heartbeat [11]. Studies have shown that
hypertension is causally involved in nearly 70% of all stroke cases [12].
The factors that can cause high blood pressure are multi-faceted. They include obesity,
drinking three or more alcoholic beverages a day, high salt intake, aging, a sedentary
lifestyle, stress, low potassium, magnesium, and calcium intake, and resistance to insulin
[13].
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The degree of economic development, culture, traditions, geography and the composition
of certain natural resources can all affect the size of high-blood-pressure population
through food intake, lifestyles and genetics. Among developed countries, scientists have
discovered some cross-country differences in the prevalence of hypertension. For
example, a study conducted in 2003 showed that the average hypertension prevalence of
six European countries (England, Finland, Germany, Italy, Spain, and Sweden) is 44.2%
for the age group of 35 to 64 years old. Among these countries as well as Canada and the
United States, Germany has the highest hypertension prevalence for the same age group
(55%) [14]. In contrast, however, the percentage of population having hypertension in
Japan is lower (a study in 1983 showed less than 20% for age group 40 to 64 years old
[15]); the Japanese government has led health campaigns aimed at reducing hypertension
in its population [16]. Some believe that the relatively low incidence of hypertension in
Japan is culture-related. For example, popular traditional Japanese food such as Natto
(made from soybeans) and fish (containing fatty acid) have been shown to help reduce
high blood pressure and/or relieve hypertension symptoms [17][18][19].
Given the above evidence, one may hypothesize that assuming 1) the same percentage of
prevalence in the overall population and 2) every hypertensive person is treated, the
overall per-capita demand for hypertensive medications in Germany is much greater
(roughly (55%-20%)= 175% more) than that in Japan. However, the data in this work
20%
shows that the per-capita sales levels of antihypertensives in Germany and Japan have a
smaller gap (per-capita sales in Germany is only 29% more than that in Japan). This
phenomenon and its possible underlying causes are illustrated and discussed in greater
detail in section 3.3.
3.2 Types of antihypertensives
As mentioned at the beginning of section 3.1, hypertension refers to an elevation of the
blood pressure in the human body. With hypertension, the blood force against the arterial
walls is abnormally high, which results in overworking of both the heart and the blood
vessels. The mechanisms of antihypertensives are then to lower blood pressure by one of
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or combination of: (1) opening and widening the blood vessels, (2) preventing the blood
vessels from closing and tightening, or (3) reducing the workload of the heart [20].
Currently, there are ten types of antihypertensives categorized by their mechanisms of
action [21]: diuretics, alpha-blockers, beta-blockers, calcium channel blockers,
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs),
central adrenergic inhibitors, peripheral adrenergic inhibitors and blood vessel dialators.
In the data and the analysis of this chapter, the most commonly used categories of
medications are included: beta-blockers, calcium channel blockers, ACE inhibitors and
ARBs. Further, the ARBs are categorized as the "new" generation of antihypertensives,
ACE inhibitors are categorized as the "middle" generation, and the remainder (beta
blockers and calcium channel blockers) are the "old" generation of antihypertensives.
Table 3.1 summarizes the different types of antihypertensives categorized by their
mechanisms of action as well as their generation [21]. (Appendix 1 gives a complete list
of the compounds included in this study.)
Table 3. 1 Categories of antihypertensives by mechanisms of action
Categories :- '-':. . ' h .- ~Of' . -' ,w ' ' " .
Reduce the workload of the heart by blocking
nervous system to release certain chemicals that
bind with beta receptors in the heart, which could
trigger a rapid heartbeat.
'cl ti ' '; ,te intt eWhib.
ACE Block the production of angiotensin II, which
i- inhibitors causes blood vessels to tighten.
j>4 hi<: .Bluc li m. hm.. the 
bl:kers t . : . < . ' '"':': .' ' '
Source: American Heart Association, http://www.americanheart.org/
in this study
Gneration
Old
New
Middle
Old
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Although positive effects of pharmacological treatment of hypertension are well
established, the outcome depends on the patient's conditions and the specific
antihypertensive medication used. Adverse outcomes were reported for short-acting
nifedipine in 1995 [22]. In 1996 an increased cancer incidence was observed in users of
calcium channel blockers (including verapamil, diltiazem and nifedipine) [23]. A recent
meta-analysis of randomized clinical trials found a significantly lower preventive
effectiveness against myocardial infarction and congestive heart failure among patients
allocated to intermediate- and long-acting calcium channel blockers than among those on
other antihypertensives [24]. Generally, the newer medications have fewer and/or less
severe side effects, which are a strong factor that boosts the sales of such medications.
Table 3.2 illustrates the generally recognized side effects of antihypertensives [21].
Despite the different side effects, there is no current agreement on which class of drug
should be initially prescribed to treat high blood pressure. Physicians prescribe
antihypertensive based on each patient's past medical history and current symptoms and
conditions, as well as their own experience. In addition, if the use of a single
antihypertensive does not lower blood pressure sufficiently, then physicians may
prescribe two or more types of antihypertensives to work in combination. Independent of
the prescription, patients are always recommended to change their lifestyle to help
control their condition.
Table 3. 2 Side effects of antihypertensives by mechanisms of action in this study
insomnia, cold hands and feet, tiredness or
Beta blockers depression, a slow heartbeat or symptoms of Old
asthma
ACE skin rash; loss of taste; a chronic dry, hacking Middle
inhibitors cough; and in rare instances, kidney damage
Source America Hea Assoiatn hmr. oig
Source: American Heart Association, http:llwww.americanheart.org
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3.3 Descriptive analysis of the sales and promotion of
antihypertensives
3.3.1 The sales of antihypertensives
Firstly, the overall antihypertensive markets in number of patient days in Germany and
Japan are plotted and compared. As shown in Figure 3.1, the sales of antihypertensives
increased steadily in both countries (0.67 to 1.83 million patient days for Germany and
0.80 to 2.05 million patient days for Japan, from first quarter of 1992 to the fourth quarter
of 2003). Between 1992 and 1999, the total sales of antihypertensives grew faster in
Japan than in Germany. (The average annual growth rates are 7.6% and 6.4%
respectively.) However, in years 2000-2003 the sales have increased more quickly in
Germany than in Japan. (The average annual growth rates of total patient days of
antihypertensives are 13.4% for Germany and 7.1% for Japan.) At the end of 2003,
Germany had a similar level of antihypertensives sales as Japan, despite the fact that it
has only about two-thirds of Japan's population.
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Figure 3. 1 Total patient days for antihypertensives in Germany and Japan
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Figure 3. 2 Total patient days per capita for antihypertensives in Germany and
Japan
The different acceleration rates of the sales in antihypertensives between Germany and
Japan can be further illustrated under the patient-days-per-capita (total patient days
divided by total population) scale in Figure 3.2. At the beginning of 1992, one German
consumed 28.9% more antihypertensives than did a Japanese (0.008 v. 0.006 patient days
per capita), and by the end of 2003, this number increased to 37.8% (0.022 v. 0.016
patient days per capita). Therefore, Germany's antihypertensive sales have been growing
faster than that of Japan. However, as mentioned at the end of section 3.1, the difference
of antihypertensives sales (per capita) between Germany and Japan remains smaller than
expected.
Despite the relatively high sales in Japan, antihypertensives seem to be more expensive in
Japan than in Germany. Figures 3.3 and 3.4 indicate the total sales per capita and the
price per patient day (derived by dividing total sales by total patient days of each year) in
purchasing power parity (PPP)-adjusted US dollars3. Figure 3.3 shows that the surplus of
total per-capita spending in antihypertensives for Japan relative to Germany started to
increase since late 1990. The per-patient-day price in Germany has been steadily
3 Local currencies were converted into PPP-adjusted US dollars in this study.
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decreasing, while remaining relatively steady in Japan since the late 90's. At the end of
year 2003, the price of antihypertensives is $0.73 in Japan, about 2.5 times of the price in
Germany at that time ($0.29).
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35
Figure 3. 3
Figure 3. 4
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The differences in per-patient-day price between Germany and Japan can be explained by
looking into the patient-day market share of each generation and the price difference by
generation of therapies. Figures 3.5 and 3.6 illustrate the change in market share of
antihypertensives over time in each country; Figures 3.7 and 3.8 are the average per-
patient-day prices of the new generation defined in section 3.2 (i.e., the ARBs).
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Figure 3. 5 Market share (in patient days) of antihypertensives in Germany
1UU/o
e 90%
.2 80%
70%
.X 60%
E 50%
>, 40%
' 30%
a 20%
10%0%
0%
o' 93 9o qo' o' o ' o . zv lS.,
-- new ------- middle old
Figure 3. 6 Market share (in patient days) of antihypertensives in Japan
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As seen in Figures 3.5 and 3.6, the share of new drugs increased over time in both
countries but this new share in Japan is higher than that in Germany (21% and 7%
respectively in the 4th quarter of 2003). The price of the new drugs, which is the highest
of all three generations, is much higher in Japan than in Germany (about $1.30 vs. $0.70
respectively at the end of 2003, as shown in Figures 3.7 and 3.8). Therefore, the
combination of higher prices and larger share of new drugs contributes to a higher
average price per patient day for all generations in Japan than that in Germany. In
addition, it is worth noting that the prices of all new compounds tend to converge in both
countries. This is likely to be a result of centralized pricing control from the
governments.
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Figure 3. 7 Price per patient day (in PPP-adjusted US$) for new
antihypertensives in Germany
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Figure 3. 8 Price per patient day (in PPP-adjusted US$) for new
antihypertensives in Japan
Among the new drugs, there are seven compounds launched in Germany and only four
compounds sold in Japan. These new compounds were also launched earlier in Germany
than in Japan; however, the sales of the new compounds grew and gained their shares in
the overall antihypertensive market much quicker in the Japanese market than in the
German market. These all suggest that the German antihypertensive market is more
mature than Japan. However, in both markets, certain compounds showed similar
performance in sales. As shown in Figures 3.9 and 3.10, candesartan cilexetil and
valsartan had the top and second-to-top sales volumes in both countries at the end of the
time period.
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Although Germany has much higher per-capita (the figures show per-million-population
values) sales of antihypertensives towards the end of the time period, the difference
between Germany and Japan is relatively small throughout the time period of our study.
This suggests that the incidence of hypertension does not simply translate into the sales of
hypertensive medications. The reasons that cause this disproportional relationship
between the "potential demand" and "real demand" are varied. For example, since
hypertension usually does not have strong symptoms, some are not detected (they are
called "masked hypertension") or treated. The Japanese government's health campaigns
have increased not only the prevention of hypertension (long-term effect on
antihypertensive sales), but also the awareness of hypertension diagnoses and treatment
(short-term effect on antihypertensive sales). Since both Germany and Japan have social
insurance systems, which offer almost full coverage of prescriptions, the disparity of drug
sales is less likely to be due to affordability of individuals. However, in such systems
there are situations that some prescribed drugs are never consumed. Thirdly, the studies
mentioned in section 3.1 were constrained to specific age groups, and the differences
among age groups in Germany and Japan are unknown. In all these cases, the projected
demand will not be reflected by the actual sales of the hypertension medications. The
actual percentage of treated hypertension depends on public awareness, medical
examination, medication options and very often direct and/or indirect economic
behaviors of pharmaceutical companies. In the following section, promotional efforts of
antihypertensives are discussed.
3.3.2 The promotion of antihypertensives
Since direct-to-consumer advertising (for prescription drugs) is prohibited in both
countries, the decision-making on drug prescription resides primarily in the physicians.
Among all types of promotional activities to physicians, detailing is the most important
promotional practice in the pharmaceutical industry. Hence the intensity of detailing is a
good indicator of overall promotional efforts. In this section, detailing activities for
antihypertensives in Germany and Japan are compared and discussed. (I note that the
detailing information in Japan is only available between 1998 and 2003.)
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Antihypertensives are much more heavily promoted in Japan than in Germany through
detailing to physicians. Figures 3.11 and 3.12 show the total detailing counts per capita
and per physician. On the class level, the number of detailing visits in Japan is about six
times that in Germany in both cases (per capita and per physician). One possible
explanation of the high detailing counts in Japan is that physicians are allowed to
dispense medicines in Japan. However in Germany this is not the case.
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Figures 3.13 and 3.14 illustrate the share of detailing counts by generation of drugs. In
both countries the new drugs reached and exceeded the detailing level of old drugs,
which dominated the early and mid stages of the market (50% for Japan and 44% for
Germany at the beginning of 1992). Comparing Figures 3.5 and 3.13 vs. 3.6 and 3.14,
the sales-to-detailing ratio of new drugs in Germany is much lower than in Japan,
implying that the Japanese market is more prone to new drugs' penetration.
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Figure 3. 13 Share of detailing counts by generation for antihypertensives in
Germany
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Figure 3. 14 Share of detailing counts by generation for antihypertensives in Japan
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The descriptive analysis has shown the co-existence of relatively high sales and rigorous
promotion at both market- and generation-level in Japan. Many previous studies,
primarily of the U.S. market, have shown that the pharmaceutical market and sales can be
positively influenced by promotion efforts and pricing strategies. Does this relation exist
in the German and the Japanese market? If yes, to what extent is the influence of
promotion on sales in this particular case? It (among other factors) will be numerically
evaluated through econometrics models in section 3.4.
3.4 Econometric analysis
In this section, the regression models at the class, generation, and product levels
discussed in chapter 2 are estimated. The models are aimed to quantitatively examine the
relationship between diffusion of medicines (sales volume and market share) and
economic, demographic and policy factors. These factors include the overall wealth of
the society (GDP per capita), availability of medical care (represented by number of
physicians per capita), promotion intensity (lagged detailing counts), regulated prices,
and age structure of the population. The right-hand-side (RHS) variables
tot_detail_capita_lagl and tot_detail_capita_lag4 are regressed in separate models
because of their high pair-wise correlation (> 0.9).
3.4.1 Therapeutic-class-level analysis
Table 3.3 shows the regression results of the log-form Equation 1 in chapter 2:
log_tot_pd_capita is the dependent variable; price, number of compounds, and detailing
information are correspondingly calculated at the class level. As seen from Table 3.3, at
the therapeutic-class-level regressions, only the time trend variable has a positive
significant parameter estimate for both countries. The percentage of people who are
older than 65 years old has a negative significant parameter estimate in Japan. All of the
other parameters are insignificant. (Detailed SAS outputs are included in Appendix 2.)
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Regression results of Equation 1 (dependent variable:
logtot_pd_capita)
Intercept
log_income_ 1Kcapita
log_phys_lMpop
pct0_14
pct65p
time
log_price_class
log_price_ratio
log_num_compound
log_tot_detail_capitalag4
log_tot_detail_capita_lag *
Number of observations
Adjusted R-square
Parameter estimate
9.75
(0.41)
0.85
(0.27)
-2.13
(-0.77)
14.56
(0.26)
6.62
(0.17)
0.03
(3.07)
0.13
(0.64)
-0.10
(-0.24)
-0.61
(-1.10)
0.13
(0.76)
0.13
(1.31)
32
0.93
13.67
(0.41)
-4.14
(-1.20)
-2.11
(-0.69)
1.31
(0.29)
-7.28
(-3.03)
0.08
(5.64)
-0.48
(-1.02)
-0.59
(-0.51)
-0.04
(-0.03)
0.18
(0.88)
-0.08
(-0.32)
22
0.86
t-values are shown in the parenthesis below the parameter estimates.
*model is run with log_tot_detail_capita_lag4 replaced by log_tot_detail_capita_lagl
Hence the class-level regression model has shown us that the total patient days including
new, middle and old generations have increased over time in both countries, which is
consistent with the descriptive analysis in section 3.3. On the other hand, the changes of
the average price and the aggregated promotion efforts were not able to explain the
expansion of the antihypertensive markets. One possible reason to explain why most
parameters are insignificant at the class-level is that much of the effects of the factors
such as detailing, competition, and prices are dampened due to the aggregation of
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Table 3. 3
Variable
Germany Japan
- -- ----
information. This calls for a need for generation- and product-level analyses of these
medications, which are discussed in the following sections.
3.4.2 Generation-level analysis
In this section, the sales of antihypertensives in number of patient days are regressed at
the generation level (Equation 2). Then the number of patient days for new drugs is used
as the dependent variable (Equation 3). The RHS variables such as price, detailing
information, and the number of compounds are adjusted accordingly to be at the
generation level. As described in Equations 2 in chapter 2, dummy variables
differentiating the generations of antihypertensives are also used. The omitted dummy
variable is the old generation.
Regression results of the linear form of Equation 2 indicate highly significant differences
among the new, middle and old generations in both countries - the negative signs of the
parameters indicate that the sales of the new-generation and the middle-generation
antihypertensives are less than that of the old generation. The values of these estimates
are listed in Table 3.4. (The detailed SAS outputs are shown in Appendix 2.) The
estimated parameters show that the absolute difference of drug saless between the new-
/middle-generation and the old-generation is smaller in Germany (-4.74 for new and
-2.36 for the middle generation) than in Japan (-9.28 for new and -3.94 for the middle
generation). It might seem contradicting to the findings in Figures 3.5 and 3.6, in which
the percentage of new generation was higher in Japan than in Germany. However, since
Germany had a larger per-capita patient-day level, the regression results reflected this
absolute value difference rather than the difference in percentage. In addition, the
interaction variable timenew and timemiddle all have significant and positive parameters.
This indicates that as time went by the new and the middle generations have increased
sales and the gap between the new and the old generation shrank, consistent with the
observation from the descriptive analysis.
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Table 3. 4 Regression results of Equation 2 (dependent variable:
log-gen_pd_capita)
Variable
Intercept
log_income_l Kcapita
log_phys_l Mpop
pctO_14
pct65p
time
log_price_ratio
log_price_gen
log_num_new_compound
new
middle
timenew
timemiddle
log_gen_detail_capita_lag 1
log_gen_detail_capitalag4*
Number of observations
Adjusted R-square
t-values are shown in the parenthesis
Parameter estimate
Germany
-43.55
(-0.81)
-3.51
(-0.43)
3.75
(0.58)
44.21
(0.35)
42.02
(0.47)
-0.0016
(-0.53)
-1.17
(-0.95)
-0.78
(-1.80)
0.32
(2.24)
-4.74
(-12.62)
-2.36
(-5.67)
0.093
(11.24)
0.048
(3.90)
-0.46
(-4.18)
-0.81
(-2.86)
99
0.960
Japan
28.60
(0.69)
6.82
(1.43)
-5.89
(-1.13)
-68.29
(-1.45)
-45.56
(-2.36)
-0.016
(-0.65)
-1.59
(-0.88)
0.44
(0.84)
0.43
(2.91)
-9.28
(-14.92)
-3.94
(-5.72)
0.19
(21.25)
0.071
(3.79)
-0.78
(-5.22)
-0.86
(-1.65)
66
0.984
below the parameter estimates.
*model is run with rel_detail_lagl replaced by rel_detail_lag4
Omitted generation variable: old
The number of new compounds has a significant and positive parameter estimates in both
countries. This might suggest that increasing the variety of the new drugs has helped to
expand the market for the new and other generations. Secondly, three out of four of the
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detailing variables have significant negative parameters. The negative sign for the
promotion variables is a result of the co-existence of the heavily detailed low-sales-level
new generation and the lightly detailed high-sales-level middle and old generations. To
be more specific, the newly launched medicines were heavily promoted (about the same
level as the old generation at the end of the time period for both Germany and Japan),
however, the sales were not able to catch up with the long-existing older generations that
are less heavily promoted. The regression results for the new generation showed a
significant positive correlation to the sales volume, which will be shown and discussed in
Table 3.5 and paragraphs that follow. Lastly, the parameter for the time variable in this
regression indicates the time trend of the old generation. It is insignificant for Germany
and Japan, which indicates that the old antihypertensives did not show a clear upward or
downward trend in the two countries.
Since one of the key goals in this work is to examine how the new generation of
medications is diffused, a regression model with number of new patient days being the
dependent variable (logarithm form of Equation 3 in chapter 2) was run to identify the
factors that contribute to the sales of the new medications. Table 3.5 shows a summary
of the regression results with the LHS variable being the share of the patient days of the
new medications (in logarithm form).
In this set of regressions, the parameter estimates of the time trend variable, population
age variables, number of new compounds and both detailing variables are significant for
Germany and Japan. Again, the positive time parameter indicates significant growth of
the new generation; the negative age parameters suggest that people aged between 15 and
65 contributed to the increase of the sales of the new drugs; the positive parameter of the
number of new compounds indicates the expansion of the new generation sales is
accompanied by the increased options for treatment within the generation. The positive
detailing parameters suggest that the more the promotional efforts, the more sales of
medicines. In addition, the lagged cumulative four quarters detailing has a stronger effect
than the lagged one quarter detailing in Germany (0.45 vs. 0.24).
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Regression results of Equation 3 (dependent variable:
log_share_new_pd)
t-values are shown in the parenthesis
*model is run with logrel_detail_lagl
below the parameter estimates.
replaced by log_rel_detail_lag4
One may have noted that none of the price/price-related variables in the above three sets
of regressions (shown in Tables 3.3 - 3.5) has a significant parameter estimate (except
for a barely significant price ratio variable for Japan in Table 3.4). This probably reflects
the fact that both Germany and Japan have social-based health care systems, which have
1) centralized price controls and 2) wide coverage for pharmaceutical expenses of their
citizens. As a result, the actual sales are relatively close to the real demand/need and are
independent from the price of the drugs. Since direct-to-consumer advertising (for
prescription drugs) is prohibited in both countries, the sales of drugs is more dependent
on the doctors' awareness and knowledge of certain medicines, which is delivered via the
means of detailing and other communications within the national health care systems.
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Table 3. 5
Parameter estimate
Germany Japan
Intercept 99.74 -17.51
(2.29) (-0.36)
logincome_ 1Kcapita -10.15 27.07
(-1.52) (3.14)
log_phys_lMpop 3.85 -5.03
(0.64) (0.74)
pct0_14 -376.92 -168.14
(-3.09) (-2.20)
pct65p -274.45 -79.59
(3.33) (-3.04)
Time 0.05 0.09
(2.24) (2.60)
logprice_ratio 0.0009 3.23
(0.00) (-0.76)
logshare_num_newcmpnd 9.87 13.96
(4.04) (2.19)
log_rel_detail_lagl 0.24 0.62
(2.08) (3.12)
log_rel_detail_lag4* 0.45 0.58
(7.73) (9.69)
Number of observations 32 21
Adjusted R-square 0.967 0.997
3.4.3 Product-level analysis
However, it is presumptuous to rush into the conclusion that these two markets are
completely price inelastic. The governments on the one hand take price control, and on
the other hand encourage using less expensive medications by policies such as co-
payment and positive/negative lists of drugs. More disaggregated product-level analyses
have shown that the pricing policy and the social-based health care systems did provide a
mechanism to realize (to some extent) price-based product selection. Table 3.6 shows the
product-level regression results, which support the above argument. (The detailed SAS
outputs are shown in Appendix 2.)
At the product level, most of the estimated parameters are significant in Germany and
more than half of the parameter estimates are significant in Japan. The negative
parameter for the product price suggests the textbook-market characteristic: the lower the
price, the higher the sales of the products. Although the demands in both countries are
relatively price inelastic (-1< price elasticity <0), Germany appears to be more price-
elastic than Japan (-0.60 vs. -0.15). This is consistent with the fact that Germany has
more competing antihypertensive medications, less control of the pricing of innovative
drugs and less-universal coverage of pharmaceutical expenses by the government [25].
In this set of regression, the dummy variables 'new' and 'middle' have positive signs in
Germany and Japan (except for middle in Japan). This is not consistent with the results
shown in Table 3.4, where all dummies have negative signs. This may be a result of high
product-level variance of the sales of new and middle generation medications. Thus at
aggregated level the variance is cancelled.
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Table 3. 6 Regression results of Equation 4 (dependent variable:
logprod_pd_capita)
Variable
Intercept
logincome_lKcapita
log_phys_lMpop
pctO_14
pct65p
time
log_price_prod
log_num_new_compound
generic
new
middle
oldgen
log_prod_detail_capita_lag 1
log_prod_detail_capita_lag4*
Number of observations
Adjusted R-square
Parameter estimate
Germany
49.65
(3.18)
-5.85
(-1.42)
1.67
(0.62)
-227.45
(-4.66)
-135.22
(-4.02)
-0.007
(-0.57)
-0.60
(-16.54)
0.011
(0.74)
-0.71
(-6.49)
1.87
(10.86)
1.04
(16.48)
0.39
(3.21)
-0.07
(-4.07)
-0.062
(-12.82)
12389
0.06
82.91
(1.14)
-30.96
(-2.88)
-0.52
(-0.06)
35.71
(0.36)
19.10
(0.41)
-0.06
(-1.21)
-0.15
(-2.63)
0.027
(0.53)
-2.50
(-7.08)
4.37
(11.10)
-0.47
(-3.98)
-0.39
(-0.93)
-0.04
(-4.53)
0.0038
(0.36)
3217
t-values are shown in the parenthesis below the parameter estimates.
*model is run with log_rel_detail_lagl4 replaced by log_rel_detail_lag4
Omitted generation variable: old
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In this regression model, some dummy variables are also added in addition to the new-
and old-generation dummies. The generic dummy variable differentiates generics drugs
(products labeled as "G" or "NA" in the IMS database) from the branded drugs. The
branded drugs are defined as products labeled with "O" (originator), "B" (other branded),
or "L" (licensee) in the IMS database. The branded drug dummy variable is omitted in
the regression. The results show that the generic drugs have fewer sales than the branded
drugs in Germany and Japan. However, Germany uses more generics than Japan (-0.71
and -2.50 respectively). This is partially because that under the social-based health care
system, since the demand price elasticity is low (as shown in the regression), the generics
substitute branded drugs more slowly than the market with greater price competition.
Japan's low price elasticity may have further slowed down the adoption of generics.
Other factors may include the patent expiration dates of each drug (drugs are launched
later in Japan than in Germany), the market share of the drugs with patent protection, and
physicians' traditional perceptions of generic drugs. The variable "oldgen" has opposite
signs in the two countries (0.39 for Germany and -0.39 for Japan, but not significant).
The positive sign indicates that the old generics have more sales than newer generics and
old branded drugs in Germany. This result is consistent with the previous studies [1] and
the findings for the generics dummy earlier in the same regression that generics are more
common in Germany than in Japan.
Three out of four promotion variables have significant negative signs in the regression
results shown in Table 3.6, contrary to the results shown in the generation-level
regressions (shown in Table 3.5). This may be a result of the heavy promotion of certain
very new products, whose sales volume has not picked up and a result of the opposite
situation for some old products. (At the aggregated generation level, this is not
differentiated.) The insignificant parameters for the time variable may result from the
same reason.
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3.5 Summary for the antihypertensive markets
In sum, the German and the Japanese antihypertensive markets have exhibited both the
effects of competitive markets and government interventions. Firstly, at the aggregated
class-level, the markets expanded over time in terms of volume (patient days) and
revenue (US$). Secondly, there is a clear difference in antihypertensive sales volume
among the three generations. In Germany the new generation had penetrated the
antihypertensive market more slowly than that in Japan, because the Germany market is
more mature and competitive. The fast increase in the share of the new generation in
Japan has resulted in a higher average price than that in Germany. In both countries, the
price controls and competition have led the prices of the various new-generation
antihypertensives to converge over time. Thirdly, detailing activities have significant
positive impact on the sales of new drugs in Germany. Finally, at the product-level the
price variable shows a low demand price elasticity of the antihypertensives. In both
countries the branded antihypertensives were used more than the generics, with Japan
being the stronger case. However, the generics were clearly used more in the old
generation than in the new and middle generation in the German market; this is not the
case for Japan, where none of the generations had dominant generic sales.
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Chapter 4 Antidepressants in Germany and Japan
In chapter 3 the market, sales patterns of antihypertensives and the factors that contribute
to them were analyzed for Germany and Japan. This chapter follows a similar structure
as in chapter 3 but instead for the case of antidepressants. Firstly, a background
discussion on depression and antidepressant medications is introduced. Following that,
descriptive analyses of the antidepressants at the class, generation and compound level
are presented. Then econometric models are used to quantify and compare the factors
that contributed to the sales and diffusion of antidepressants during 1992-2003 in
Germany and Japan. Finally, a summary based on the descriptive and econometric
analyses is presented at the end of this chapter.
4.1 Symptoms and causes of depressive disorders
Depression is a serious medical illness. Typical symptoms of depression are a persistent
sad, anxious, or "empty" mood, feelings of hopelessness, guilt, worthlessness,
helplessness, pessimism, loss of interest or pleasure in hobbies and activities that were
once enjoyed [26]. There are three most common types of depression: (1) Major
depression: It can disable one's ability to work, study, sleep, eat, and enjoy once
pleasurable activities. Major depression can occur once or several times in a lifetime. (2)
Dysthymia: It is less severe than the major depression. It involves chronic symptoms
that keep one from functioning well or from feeling good. (3) Bipolar disorder: Bipolar
disorder is also called manic-depressive illness. It is characterized by cycling mood
changes: severe highs (mania) and lows (depression) [26].
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Untreated depression has many negative effects. They include: reduced ability to fight
infection; resistance to seek for or comply with treatment of illnesses; sleep deprivation;
alcohol and drug abuse; reduced ability in work life, family life, and social life; and
suicidal behaviors [27].
The biological causation of depression remains unclear, albeit it is widely recognized by
scientists that people suffering from depressive disorder have smaller hippocampus (a
small part of brain) than people who do not suffer from depression. A smaller
hippocampus has fewer serotonin receptors, which is a chemical messenger that allows
communication between nerves in the brain and the body (also called neurotransmitter)
[27]. Hence the medications for depression are aimed to increase either the amount of
serotonin or the neurotransmitters in the patients' brain.
Although scientists have not found out why depressed people have a smaller
hippocampus, they do realize some of genetic the factors that can lead to depression.
Firstly, some onsets of depression can be 'inherited'. Some types of depression (such as
bipolar disorder) are passed from parents to children, suggesting a biological
vulnerability that is transferred genetically [26]. Studies have also shown that depression
can be gender-related: women experience depression about twice as often as men, related
to hormonal variation [28].
However, there are many people with depression whose families do not have a history of
depression. Thus non-genetic factors such as major changes in life patterns, financial
burdens, serious illnesses (such as stroke, Parkinson's disease), and other stresses at
home, work, or school may contribute to the onset of depression. Usually the onset of
depression is due to a combination of several of the factors mentioned above.
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4.2 Cultural factors of the prevalence and treatment of
depression
Similar to hypertension and many other diseases or conditions, the prevalence of
depression and percentage of treated patients are closely related to regional culture and
tradition. In particular, Japan has distinct differences in diagnosis and treatment of
depression from Germany, other parts of Europe, and the U.S. due to cultural origins.
These reasons are briefly discussed in this section.
Mental illness has long been stigmatized and inadequately addressed in Japan [29]. The
suicide rate was one of the highest among developed countries (24.1 per 100,000
population in 2000) [30]. In an epidemiological study 29.9% of a population randomly
selected from 300 communities in Japan had depression [31]. The prevalent ignorance of
depression and other mental illnesses by the Japanese public comes from deep cultural
roots. Traditionally, Japanese people consider depressive symptoms as natural or just a
sign of an individual's weaknesses, instead of a medical condition. As a Japanese
psychiatrist Tooru Takahashi described, "Melancholia, sensitivity, fragility - theses are
not negative things in a Japanese context... It never occurred to us that we should try to
remove them." [29] The word for "depression" traditionally referred only to major or
manic depressive disorders and was seldom heard outside psychiatric circles. The
mentally ill are seen to bring shame to one's family name [32]. Even the medical
professionals' awareness of depression was extremely insufficient. Naoki Watanabe, an
expert in suicide and depression said in an interview with the BBC News, "Doctors and
nurses in Japan are not trained to recognize depression." [33] As a result, the sales of
antidepressants were very low before the late 1990's. Eli Lily, the manufacturer of
Prozac (the U.S. product name of fluoxetine) found virtually no demand for
antidepressants in Japan when it intended to introduce Prozac to the Japanese market in
the 1980's [29].
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Only beginning in 1999, a Japanese company (Meiji Seika Kaisha) started to promote
depromel (product name of fluvoxamine in Japan), a more than 10 years' delay from the
same drug being marketed in Europe and the United States [34]. One year later,
GlaxoSmithKline entered the Japanese market with its product Paxil (product name of
paroxetine). Both companies marketed their antidepressants with a nation-wide
education campaign for depression [29]. At the same time, the Japanese government
conducted health campaign as well. These campaigns have successfully increased much
awareness of depression in the public and among medical professionals. As a result, the
antidepressant market in Japan started to expand quickly.
Among the developed countries other than Japan, Germany has relatively high prevalence
of depression (about 9.2% in West Germany in 1996 [35]) and low percentage of treated
patients (35% [36] of those, i.e. about 3% of the total population). In addition, Germany
has slightly higher percentage of females during the time period (shown in Figure 1.5),
who are more susceptible to depression than men. However, as compared to Japan, the
prevalence of depression in Germany is lower. In addition, the awareness and treatment
of depression has a much longer history than in Japan; therefore the percentage of treated
patients is much higher. As will be shown in section 4.3, Germany also has a more
varied selection of antidepressant medications than does Japan.
Given the above facts, one may hypothesize that although both markets for
antidepressants have grown due to the increased awareness and diagnostics, the Japanese
market would be smaller than the German market (on a per-capita scale); and the sales of
antidepressants in the Japanese market would show a more dramatic take-off starting
from the late 90's. The results of the data analysis in this work are consistent with these
hypotheses. For example, the per-capita sales levels of antidepressants in Germany and
Japan have a large gap (per-capita sales in Germany is 1.5 time of that in Japan in 2003).
This, together with other findings, is illustrated and discussed in greater detail in section
4.3.
4.3 Types of antidepressants
Despite the heterogeneous prevalence and recognition, depression has drawn more and
more attention from doctors, researchers, governments, and the public in many countries.
Research and development of treatments for depressive disorders have been conducted by
government- and industry-funded projects. Currently, there are four common types of
antidepressants categorized by their mechanisms of action: tricyclic antidepressants
(TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors
(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) [27]. The newer
generation of antidepressants (such as SSRIs) generally has fewer side effects than the
older generation (such as the TCAs) [26].
In the analysis of this work, two generations of medications are defined by mechanisms
of action and the time they have been in the market. The SSRIs, the SNRIs and a few
other newer antidepressants (bupropion and mirtazapine) are categorized as the "new"
generation; TCAs, MAOIs, mood stabilizers and psycho stimulants are classified as the
"old" generation. There is no "middle" generation for antidepressants in this chapter.
Table 4.1 summarizes the different types and side effects of antidepressants sorted by
their mechanisms of action as well as their generations [27]. Appendix 3 gives a
complete list of the compounds included in this study.
Although in general the new generation of antidepressants has fewer side effects than the
old generation, the efficacy and reaction to medication depend on individual patients.
Usually the physicians will try a variety of antidepressants (and dosages) before finding
the most effective medication or combination of medications [26].
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Table 4. 1 Categories and side effects of antidepressants by mechanisms of
action in this study
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Increase the amount of
TCAs serotonin and/or
norepinephrine in the
brain
Dry mouth, blurred vision,
increased fatigue and sleepiness,
weight gain, muscle twitching
(tremors), constipation, bladder
problems such as urine retention,
dizziness, daytime drowsiness,
increased heart rate, sexual
problems.
Reversible sexual problems,
Increase the amount of dizziness, headaches, nausea
serotonin in the brain right after a dose, insomnia,
feeling jittery
Old
New
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Source: www. WebMD.com
Besides the above-mentioned medications, there are other treatments for depressions such
as electroconvulsive therapy (ECT), psychotherapies and herbal medicines. Herbal
medications (such as St. John's Wort) for treating depression are used in Europe and
some Asian countries. However, the actual sales of such medication are relatively small
and difficult to estimate (as they are usually sold as diet supplements). Due to the
constraints of data availability, they are not included in this study.
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4.4 Descriptive analysis of the sales and promotion of
antidepressants
4.4.1 The sales of antidepressants
Firstly, the overall antidepressant markets in number of patient days in Germany and
Japan are plotted and compared (during 1992-2003). As shown in Figure 4.1, the total
sales of antidepressant tripled in Germany (from 0.11 to 0.30 million patient days) and
Japan (from 0.06 to 0.18 million patient days) during the time period. In Japan, two
stages with distinct sales growth rates of antidepressants can be observed: The first stage
is from 1992 to 1998 (7 years), in which the yearly sales grew by 0.08 million patient
days (from 0.28 to 0.36 million patient days); the second stage is between 1999 and 2003
(5 years), in which the yearly sales increased by 0.23 million patient days (from 0.41 to
nearly 0.65 thousand patient days). This is consistent with the hypothesis made at the
end of section 4.1 that the Japanese antidepressant market experienced a large expansion
after the introduction of fluvoxamine and paroxetine in the late 1990's, accompanied by
massive educational and promotional campaigns. In contrast, the growth in Germany is
more evenly distributed over the time period than that in Japan.
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Figure 4. 1 Total patient days for antidepressants in Germany and Japan
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Figure 4. 2 Total patient days per capita for antidepressants in Germany and
Japan
The characteristics of the antidepressant markets in Germany and Japan are further
illustrated under the patient-days-per-capita scale in Figure 4.2. The German market
shows a steeper growth on a per-capita scale and the two stages in the Japanese market
appear to have a clearer distinction in sales volumes at the beginning of year 1999.
Figures 4.3 and 4.4 are the price per patient day (total sales divided by total patient days
of each year) and the total sales in PPP-adjusted US dollars. Unlike the price for the
antihypertensives shown in chapter 3, neither Germany nor Japan had consistent higher
prices for antidepressants during the whole time period of the study. The average prices
of antidepressants in Germany and Japan were kept to similar levels from 1992 to the 2"d
quarter of 1999. Starting from the 3rd quarter in 1999, the average price in Japan became
consistently higher than that in Germany until the end of the data, and this price
difference kept increasing over time. As shown in Figure 4.4, the total US$ sales in
Japan almost reached the same level as that in Germany in 2003, despite the fact that
Germany had about 40% more sales volume (patient days) than Japan (shown in Figure
4.1).
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Figure 4. 3 Price per patient day (in PPP-adjusted US$) for antidepressants
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Figure 4. 4 Total sales (in PPP-adjusted US$) for antidepressants
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The difference in per-patient-day price between Germany and Japan partially results from
the same reason as in the antihypertensives case: The expensive new drugs had a higher
share in Japan than that in Germany in the last 4-5 years of the time period and lower
share in the first 7-8 years. Figures 4.5 and 4.6 illustrate the change of the market share
of new and old generations of antidepressants over time in each country. (The
generations are defined in section 3.2.)
As shown in Figures 4.5 and 4.6, the new generation existed in the German market for
the whole time period, but only comprised less than 30% of the total market share at the
end of 2003. In Japan although the new generation was introduced much later (in 1999),
the market share of the new generation was able to grow quickly and reached almost 40%
of the total market sales by 2003.
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Figure 4. 5 Market share (in patient days) of antidepressants in Germany
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Figure 4. 6 Market share (in patient days) of antidepressants in Japan
Figures 4.7 and 4.8 are the average per-patient-day prices of the new compounds. The
prices of new compounds in Germany experienced a converging trend and diverged again
in the last three years in the time period, ranging from $0.45 to $1.80. This is different
from what is observed in the antihypertensives case, where the prices converged but did
not diverge again. The reason for this phenomenon is that among the new drugs, the ones
that were launched relatively late (such as venlafaxine and sertraline) remained at their
price levels since launch until 2003; however, the ones that were launched relatively early
(such as paroxetine and fluoxetine) had price decrease because generic versions started to
enter the market, which are cheaper than the branded version. Since the prices shown in
Figure 4.7 are averaged branded and generic drug prices, they decrease as generics
entered the market. In Japan, there were only 2 new compounds launched in the market,
and the prices were $1.04 and $1.84 at the end of the time period respectively. In both
countries, the prices generally had a downward trend.
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in Japan
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As seen in the above figures, nine new compounds were launched in Germany and only
two compounds were sold in Japan. Figures 4.9 and 4.10 illustrate the patient days per
million population for each of these compounds in both countries. In Germany,
citalopram turned out to be the biggest player in the market, reaching over 0.00035
patient days per capita in the fourth quarter of 2003. However, fluvoxamine and
paroxetine, the two compounds that were successfully marketed in Japan did not do as
well in the German market. This may be due to the more intensive competition in the
market and from the new entrants that might be more technologically advanced (such as
citalopram and sertraline).
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Figure 4.9 Patient days per million population for new antidepressants in
Germany
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Figure 4.10 Patient days per million population for new antidepressants in Japan
In sum, both the Germany and Japanese markets showed a growing trend for the sales of
antidepressants in patient-day and US$ units. As a more mature market, Germany shows
the following characteristics as compared to Japan: (1) Germany has a larger total sales
and per capita sales than Japan; (2) The growth in Germany is more modest and steady
than that in Japan; (3) The German market adopted the new drugs earlier and has more
competing compounds within the new generation. The large difference in the average
prices in the two markets at the second half of time period does not necessarily suggest
that the drugs are overpriced in Japan. This is because many drugs were launched in
Japan later than in Germany, and the prices of drugs are usually negatively correlated
with time in both countries, i.e., a downward trend over time due to the decrease of
branded drug prices and the launching of cheaper generics after patent expiration. If we
compare the first-year-after-launch prices of the 2 new compounds existing in both
markets, the prices are very similar in both countries. (The price for fluvoxamine was
even higher in Germany.) Hence the seemingly high price in Japan is partially a result of
delayed launches of certain compounds. The fast growth of the new generation (in share
volume) in Japan may have been a result of less competition and the government health
campaign as well as promotions by pharmaceutical companies.
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4.4.2 The promotion of antidepressants
In this section, detailing activities for the promotion of antidepressants in Germany and
Japan are compared and discussed (again, note that the detailing information in Japan is
only available between 1998 and 2003).
Similar to the case of antihypertensives, antidepressants are more heavily promoted in
Japan at the end of the time period than in Germany through detailing to physicians
because of the launches of the new compounds. Figures 4.11 and 4.12 show the
promotional efforts in total detailing counts per-million-population and per-million-
physicians scales. There is a sharp increase for detailing counts in Japan in 1999, due to
the heavy promotion by Meiji Seika Kaisha and GlaxoSmithKline, manufacturers of
fluvoxamine and paroxetine.
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Figure 4.11 Total detailing counts per million population for antidepressants
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Figure 4.12 Total detailing counts per million physicians for antidepressants
Figures 4.13 and 4.14 illustrate the share of detailing counts by generation of drugs. In
both countries the new drugs reached and exceeded the level of old drugs at the end of
2003. However, in Germany the share of new and old drugs are at similar levels (about
50% for both generations); while the new drugs in Japan dominated in sales volume since
launch (about 80% of the market share). In addition, the growth of the new generation is
more gradual in Germany, as compared to a high share level since launch in Japan.
Recall that in the antihypertensives case, the share of new medication had a steady
growth in Japan and in Germany.
In conclusion, the descriptive analysis has shown distinct patterns of sales and promotion
activities in Germany and Japan. In Germany, the antidepressant market is relatively
mature, and the data shows more competition and less abrupt changes. In Japan, the new
generation of antidepressants shows a successful growth since launch and has expanded
the overall market as well. Similar to the Japanese antihypertensive market, the relatively
high sales of new antidepressants come with vigorous promotional efforts. In the next
I__^ _··_ _ I I __
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section, the relationship of sales and promotion as well as other factors will be examined
quantitatively using regression models.
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Figure 4.13 Share of detailing counts by generation for antidepressants in
Germany
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Figure 4.14 Share of detailing counts by generation for antidepressants in Japan
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4.5 Econometric analysis
In this section, the same regression models (Equations 1-4) introduced in chapter 2 and
used in chapter 3 are adopted to examine quantitatively the relationship between the
diffusion of antidepressants and economic, demographic and policy factors. To recap,
these factors are: 1) the overall wealth of the society (GDP per capita), 2) availability of
medical care (represented by number of physicians per capita), 3) promotion intensity
(lagged detailing counts), 4) regulated prices, and 5) age structure of the population.
Again, the right-hand-side (RHS) variable tot_detail_capita_lagl appears in separate
regressions from tot_detail_capita_lag4 in all of the regressions due to their high pair-
wise correlation. In the following sections 4.4.1 - 4.4.3 the class-, generation- and
product-level analyses are discussed.
4.5.1 Therapeutic-class-level analysis
The regression outputs of the logarithmic form of Equation 1 in chapter 2 for the
antidepressant medications in Germany and Japan are shown in Table 4.2. (Detailed SAS
outputs are included in Appendix 4.) The dependent variable is the total patient days per
capita at therapeutic class level (log_totpd_capita); the RHS variables (price, number of
compounds, and detailing information) were also calculated at the therapeutic class level.
As seen from Table 4.2, the time trend variable has significant parameter estimates for
both countries (0.03 for Germany and 0.15 for Japan). This is similar to the findings for
the antihypertensives in chapter 3, in which the parameters are positive and significant
(0.03 for Germany and 0.08 for Japan).
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Regression results of Equation 1 (dependent variable:
log-tot_pd_apita)
Intercept
log_income_l Kcapita
log_phys_lMpop
pctO_14
pct65p
time
log_price_class
log_price_ratio
log_num_compound
log_tot_detail_capitalag 
log_tot_detail_capita_lag4*
Number of observations
Adjusted R-square
Parameter estimate
82.55
(1.75)
-10.16
(-1.81)
-9.16
(-1.67)
2.76
(0.37)
-6.23
(-2.06)
0.15
(4.64)
-1.14
(-2.09)
1.37
(1.91)
-0.84
(-1.13)
-0.053
(-1.27)
0.0021
(0.03)
19
0.924
30.98
(2.14)
0.59
(0.36)
-1.83
(-1.59)
8.45
(2.44)
6.15
(2.36)
0.026
(3.24)
0.29
(2.01)
0.71
(3.85)
0.66
(1.70)
0.086
(1.13)
0.069
(1.54)
46
0.955
t-values are shown in the parenthesis below the parameter estimates.
*model is run with log_tot_detail_capita_lagl replaced by log_tot_detail_capita_lag4
The age structure variable pct65p (percentage of people who are 65 or older) are
significant for both countries but with opposite signs (6.15 for Germany and -6.23 for
Japan). This is consistent with the studies that the Japanese senior people tend not to
treat their depression [32]. Hence the decrease of pct65p over time did not drive down
the sales of the antidepressants in Japan.
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Table 4. 2
Variable
Germany Japan
..
L
The price variable log_price_class also have significant parameter estimates in Germany
and Japan. This seems to be different from the case for the antihypertensives, where the
class-level price variables are insignificant. However, the absolute values of the t-
statistics for these variables in Table 4.2 are low (only about 2). As was explained in
chapter 3, the price elasticity at aggregated levels could be less representative than that at
the disaggregated level. The price elasticities at generation and product levels are
illustrated and analyzed in sections 4.4.2 and 4.4.3.
4.5.2 Generation-level analysis
In this section, the sales of antidepressants in number of patient days are regressed at the
generation level (Equation 2). Following that, Equation 3 with the number of patient
days for new drugs only being the dependent variable is applied to the data. Similar to
chapter 3, the RHS variables such as price, detailing information, and the number of
compounds are adjusted accordingly to be at the generation level. As described in
Equation 2 in chapter 2, dummy variables differentiating the generations of
antihypertensives are used (with the old generation as omitted variable). The omitted
dummy variable is the old generation. The regression results of Equation 2 (in
logarithmic form) and Equation 3 (in linear form) are shown in Tables 4.3 and 4.4 (The
detailed SAS outputs are shown in Appendix 4.).
The results illustrated in Table 4.3 for antidepressants are somewhat similar to the results
for the antihypertensives (in Table 3.4). Firstly, the difference between the new
generation and the old generation is highly significant. In both countries, the new
generation has negative parameters, indicating a dominance of the old generation in sales
volume. The absolute difference of drug sales between the new generation and the old
generation is smaller in Germany (-3.35) than in Japan (-4.07).
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Regression results of Equation 2 (dependent variable:
loggen_pd_capita)
Intercept
log_income_lKcapita
log_phys_lMpop
pctO_14
pct65p
time
log_price_ratio
log_price_gen
log_num_new_compound
new
timenew
log_gen_detail_capita_lag4
log_gen_detail_capita_lag *
Number of observations
Adjusted R-square
Germany
-30.65
(-3.50)
-5.00
(-2.04)
4.88
(2.52)
-6.28
(-0.27)
5.74
(0.37)
0.0068
(0.94)
0.33
(2.47)
-0.44
(-3.88)
0.24
(3.91)
-3.35
(-15.26)
0.059
(26.19)
0.063
(1.20)
-0.053
(-1.47)
88
0.997
t-values are shown in the parenthesis below the parameter estimates.
*model is run with rel_detail_lag4 replaced by rel_detail_lagl
Omitted generation variable: old
Secondly, the number of new compounds has significant and positive parameter estimates
in both countries. This again suggests that the increasing variety of the new drugs has
been coupled with the expansion of the market for the new and the old generations.
However, in Japan the parameter estimate has a very low significant t-statistic. This is
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-53.40
(-1.53)
-8.77
(-1.46)
8.62
(1.84)
124.24
(2.22)
-27.40
(-1.50)
0.046
(3.03)
-0.84
(-1.49)
-0.11
(-0.39)
0.24
(2.00)
-4.07
(-13.68)
0.081
(12.98)
0.47
(5.30)
0.0056
(0.06)
38
0.987
Table 4. 3
Parameter estimateVariable Japan
.
because there are only two new compounds launched during the time period (shown in
sections 4.1 and 4.3), hence the effect of the change of new compounds is not as clear as
that in Germany, where there are nine new compounds in the market.
Finally, the interactive variable timenew have significant and positive parameters in both
countries. This indicates that as time went by the new generations had faster increasing
in sales than the old generation.
Table 4.3 also showed some results that are different from those in Table 3.4 in chapter 3.
First, in Table 3.4 three out of four of the detailing variables have significant negative
parameters. However, in Table 4.3 there is only one (log_gen_detailcapita_lag4 for
Japan) that is positive and significant. A possible explanation for the insignificant
promotion variables is that they are a result of the co-existence of the heavily detailed
low-sales-level new generation and the lightly detailed high-sales-level middle and old
generations. Secondly, the parameter for the time variable in Table 4.3 is significant for
Japan, as compared to the insignificant parameters for the antihypertensives in chapter 3.
These indicate that in Japan the overall trend for both new and old generations is to
increase over time. However, in Germany the old generation experienced decreasing
sales over certain period of time, accompanied by the increasing sales of the new
generation. Thirdly, two of the demographic and economic variables are significant in
Germany: logincome_lKcapita (-5.00) and log_phys_lMpop (4.88). This may suggest
that the generation-level sales of the antidepressants are related to the number of
physicians in Germany. However, the decrease of GDP does not decrease the sales of
antidepressants.
The new generation was then separated from the old generation; Table 4.4 shows a
summary of the regression result with the LHS variable being the share of the patient
days of the new medications (the linear form of Equation 3).
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Table 4. 4 Regression results of Equation 3 (dependent variable: share_new_pd)
Parameter estimate
Germany Japan
Intercept 2.00 -1.20
(2.39) (-1.27)
income_lKcapita 0.005 -0.030
(0.57) (-0.73)
phys_lMpop -0.00010 -0.00010
(-2.18) (-0.45)
pct0_14 -6.33 9.54
(-2.11) (1.15)
pct65p -4.14 2.29(-2.02) (0.98)
time 0.0071 0.016
(7.57) (10.43)
price ratio -0.019 -0.0043
(-4.31) (-0.26)
share_numnewcmpnd -0.61 -0.14(-10.46) (-0.74)
rel_detail_lagl 0.019 -0.0034
(2.17) (-1.68)
rel_detail_lag4* 0.0079 -0.00018
(1.96) (-0.29)
Number of observations 46 18
Adjusted R-square 0.989 0.994
t-values are shown in the parenthesis below the parameter estimates.
*model is run with log_rel_detail_lagl replaced by log_rel_detail_lag4
In this set of regression, the parameter estimates for the time trend variable are positive
and significant at the 95% confidence level for both countries. This result is consistent
with the regression for the new antihypertensives, where in both Germany and Japan the
new generation gained its sales volume with time. In Germany, the age variables have
negative parameters, which suggest that people aged between 15 and 65 contributed to
the increase of the sales of the new drugs.
The price ratio variable and the share of the number of new compounds variable both are
negative and significant in Germany. The price ratio variable indicates a relationship
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between demand and the relative price of the available products: the higher the new
drugs' prices as compared to the old drugs' prices, the less the sales of the new drug as
compared to the old drugs. The negative sign for the share of number of new compounds
may suggest that the number of old drugs increased over time at a faster speed than the
new drugs.
The regression results in Table 4.4 do not display a clear relationship of the lagged
relative detailing and sales of new drugs. In Table 3.5 all of the relative detailing
variables are significant, however, in Table 4.4 only the lagged cumulative 4-quarter
relative detailing is significant in Germany (0.019). The insignificance of the detailing
variable is probably caused by the increase in the level of detailing for the old generation
in response of the promotion of the new generation. Significant parameter estimates are
found when the relative detailing variable is substituted by the level of detailing counts of
the new drugs (not shown in Table 4.4).
4.5.3 Product-level analysis
In chapter 3 the product-level analyses for the antihypertensives have shown that the
pricing policy and the social-based health care systems could provide a mechanism to
realize certain price-based product selection. Table 4.5 shows the product-level
regression results for the antidepressants, which supports the above argument for the
German market. (SAS outputs of the regression in Table 4.5 are shown in Appendix 4.)
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Regression results of Equation 4 (dependent variable:
logprod_pd_capita)
Intercept
logincome_l Kcapita
log_phys_lMpop
pctO_14
pct65p
time
log_price_prod
log_num_new_compound
generic
new
log_prod_detail_capita_lag 
log_prod_detail_capita_lag4*
Number of observations
Adjusted R-square
Germany
27.14
(1.25)
-6.23
(-1.05)
4.81
(1.17)
-254.90
(-3.19)
-122.06
(-2.27)
-0.033
(-1.72)
-0.24
(-4.07)
0.26
(1.27)
0.32
(4.39)
0.20
(1.67)
-0.040
(-7.41)
-0.016
(-2.50)
5739
0.034
46.19
(0.48)
-2.54
(-0.17)
-4.19
(-0.35)
-62.83
(-0.56)
-62.37
(-1.00)
0.08
(1.21)
0.27
(2.12)
-0.073
(-1.21)
-1.12
(-2.72)
2.03
(6.08)
0.066
(5.28)
-0.034
(-1.51)
670
0.148
t-values are shown in the parenthesis below the parameter estimates.
*model is run with log_rel_detail_lagl4 replaced by log_rel_detail_lag4
Omitted generation variable: old
At the product level, the parameter for the product price in Germany is negative (-0.24),
which suggests the competitive market characteristic: the lower the price, the higher the
sales of the products. But the demand is relatively inelastic. However, in Japan this
parameter is positive and significant (0.27). This is a result of the special situation for
antidepressants' diffusion in Japan: the government (as well as the industry) has jointly
promoted the adoption of the new generation of antidepressants, which are more
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Table 4. 5
Parameter estimateVariable Japan
.
expensive than the old generation. Because of the high health care insurance coverage,
the drugs that have more advanced efficacy are used regardless of the higher prices. The
higher sales of the more expensive medications has driven the price variable to appear
positive. (In contrast, in Germany the more competing antidepressant medications, more
space for price-setting and possibly because of the less health care coverage [25] have
resulted in a more competitive demand elasticity.)
As a reminder, the 'generic' dummy variable differentiates generics drugs (products
labeled as "G" or "NA" in the IMS database) from the branded drugs. The branded
(omitted) drugs are defined as products labeled with "O" (originator), "B" (branded), or
"L" (licensee) in the IMS database. The results show that the generic drugs are more
widely used in Germany (0.32) than in Japan (-1.12). This finding is consistent with that
in chapter 3 (Table 3.6). However, for the antidepressant case, generics are used more
than the branded drugs, as compared to the antihypertensive case where generics are used
less in Germany. This is partially because many of the new branded antidepressant drugs
have lost their patent protection in Germany.
Both of the promotion variables have significant negative signs in Germany (shown in
Table 4.5), a same non-intuitive result as that in Table 3.6. Again, this may be a result of
the heavy promotion of certain very new products, whose sales volume has not picked up
and a result of the opposite situation for some old products. However in Japan, there
were only two compounds available in the market, which are more homogenous in terms
of their launch time and promotional patterns.
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4.6 Summary for the antidepressant markets
In summary, the German and the Japanese antihypertensive markets have shown
evidence of the effects of competitive markets and government interventions. However,
as compared to the antihypertensive market, the non-economic factors (such as culture
and government intervention) played a more important role in the sales of antidepressant
in Japan.
At the therapeutic-class-level, the markets expanded significantly over time in terms of
volume (patient days) and revenue (US$) in both countries. In Japan there is a clear
distinction of two stages in terms of the sales of the antidepressants. This is a result of
tradition and educational campaigns conducted by the pharmaceutical industry and the
government.
Similar to the antihypertensive markets, there is a clear difference in antidepressants sales
volume between the new and the old generations (new < old). In Germany the new
generation included a greater number of compounds and was launched earlier than that in
Japan, but penetrated the antihypertensive market more slowly than that in Japan, because
the Germany market is more mature and competitive. Although in Japan there were only
two new compounds in the market, the number of new compounds showed positive and
significant correlation with the generation-level patient day sales in both markets.
The averaged price level of antidepressants is higher in the Japanese market since the
later launch of the more expensive new medications. Before that, the prices of
antidepressants were at similar levels in the two countries. In both countries, the price
level exhibited an approximately downward trend. In contrast to the antihypertensive
prices, the new antidepressant prices diverged at the end of the time period in Germany
due to the launches of several new compounds.
The price variables do not have very significant parameters at the aggregated class and
generation levels. At the product level, Germany and Japan had opposite signs for their
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price elasticities. (Remember for the antihypertensives both elasticities are negative.)
This demonstrates that in Germany the demand is relatively inelastic to prices and that
antidepressant sales in Japan has been heavily influenced by cultural and health care
policy factors than the price factor. This pattern of the sales of the new-generation
medications in the Japanese market can also be shown in the regression of share_new_pd
(in Table 4.4).
Between the two therapeutic classes, the detailing activities for antidepressants have less
significant impact on the sales of new drugs in Germany and Japan than for the
antihypertensives. In contrast to the antihypertensives case, the detailing effects of the
antidepressants are not very clear at all levels (class, generation, and product) for the two
countries.
Finally, in Germany the generic antidepressants are used more than the branded drugs,
with Japan being the opposite case. Overall, Germany appears to be a more competition-
driven market than Japan, in terms of the variety of products in the market, the price
elasticity, the effects of detailing, and the adoption of generic drugs.
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Chapter 5 Cross-country and cross-therapeutic-class
comparison and conclusion
Using regression models, in this chapter I examine the cross-country and cross-
therapeutic-class differences in factors that affect the diffusion of antihypertensives and
antidepressants in Germany and Japan. Instead of separating the data by country and
therapeutic classes (as in chapters 3 and 4), I pool the regression data and add country
and class dummy variables into the regression models. The regressions in the following
sections are at therapeutic class, generation and product levels respectively. For each set
of regression, I conduct Chow tests to check whether there are differences in the
parameter estimates between the two countries and the two therapeutic classes.
5.1 Cross-country and cross-therapeutic-class comparison
5.1.1 Therapeutic-class-level regression
The regression outputs of the linear form of Equation 5 in chapter 2 for the
antihypertensive and antidepressant medications in Germany and Japan are presented in
Table 5.1. (Detailed SAS outputs are included in Appendix 5.) The dependent variable
is the total patient days per capita at therapeutic class level (log_totLpd_capita); the RHS
variables include price, number of compounds, detailing information, demographic
information, country dummy and therapeutic class dummy variable. (Japan and
antidepressants are the omitted reference groups.)
As seen from Table 5.1, the country dummy variable "Germany" has a positive and
significant parameter estimate (0.021). This means that the per-capita sales of the two
medications are higher in Germany than in Japan. Similarly, the therapeutic class
dummy variable "antihypertensives" is positive and significant (0.011), which implies
that the antihypertensives are utilized more than the antidepressants in the two countries.
The parameters of the two dummy variables suggest that assuming all of the other
variables fixed, the sales of antidepressants in Germany has 0.021 patient days per capita
more than in Japan; and the sales of antihypertensives in Germany is (0.021+0.011) =
0.032 patient days per capita than the sales of antidepressants in Japan.
Equation 5 only allows the intercepts of the two countries and the two therapeutic classes
to be different. In order to further examine if the parameter estimates are statistically
significantly different across country and therapeutic class, a Chow test is performed: the
H0 hypothesis is that there is no cross-country or cross therapeutic-class difference in the
parameter estimates (the details of how the Chow-statistic is calculated was discussed in
chapter 2). At the class level, the unrestricted sum of squared residuals (SSRU) of the
logarithm model is 0.241, and the semi-restricted sum of squared residuals SSRsr = 0.838.
With N = 120, k = 40, and q = 28, the Chow-statistic = 7.055 F2 80. The critical value
at 5%-significance level is 1.617, which is smaller than the Chow-statistic. Hence the
null hypothesis is rejected. Therefore, the Chow test has shown that the there are
significant cross-country and/or cross-therapeutic-class differences in the sales of
antihypertensives and antidepressants at the therapeutic-class level. Comparing Tables
3.3 and 4.2, the cross-country difference is small for the antihypertensives but relatively
large for the antidepressants. (For example, the parameter estimates for log_price_class
as well as pct65p have opposite signs for the two countries.)
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Table 5. 1 Regression results of Equation 5 (dependent variable: totpd_capita)
Intercept
incomel Kcapita
phys_lMpop
pct0_14
pct65p
time
price_class
price_ratio
num_compound
Germany
antihypertensives
tot_detail_capita_lag 
tot_detail_capita_lag4*
Number of observations
Adjusted R-square
t-values are shown in the parenthesis below the parameter estimates.
*model is run with log_tot_detail_capita_lagl replaced by log_tot_detail_capita_lag4
omitted variables: Japan, antidepressants
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Parameter estimate
0.029
(1.49)
-0.00013
(-0.26)
-0.000015
(-6.50)
-0.031
(-0.46)
-0.020
(-0.47)
0.00030
(6.60)
-0.0074
(-5.45)
0.0012
(8.21)
-0.000014
(-0.48)
0.021
(6.74)
0.011
(18.15)
158.12
(3.33)
41.92
(4.03)
120
0.982
17- - Variable
5.1.2 Generation-level regression
In this section results are presented for two regressions. Firstly, the sales of
antihypertensives and antidepressants are regressed at the generation level (Equation 6 in
chapter 2). Secondly, the new generation is regressed as described in Equation 7. Again,
country and therapeutic class dummy variables are added into the RHS variables in
addition to price, detailing information, and the number of compounds, demographic
variables, dummy variables differentiating the generations of medications. The
corresponding reference cases are the old generation, Japan, and antidepressants. The
regression results of Equation 6 (in linear form) and Equation 7 (in linear form) are
shown in Tables 5.2 and 5.3. (The detailed SAS outputs are shown in Appendix 5.)
The results of the generation-level regression in Table 5.2 indicate positive and
significant parameter estimate for the "antihypertensive" dummy variable (0.0069). This
result is consistent with that shown in Table 5.1, but has a smaller magnitude here.
However, the parameter estimate for "Germany" is insignificant at 95% confidence level.
This implies that the sales have a clear cross-class difference, but not a cross-country
difference at the generation level, assuming the other parameters are the same.
Similar to the generation-level regression, the parameter estimate for the country dummy
"Germany" in the new-generation share equation is insignificant (shown in Table 5.3).
However, the new-generation share regression showed a different result from the class-
and the generation-level regression for the therapeutic class dummy variable. As shown
in Table 5.3, the "antihypertensives" variable has a negative and significant parameter
estimate (equals to -0.24). This indicates that, for the new-generation medications, the
share of new antihypertensives sales has a 24% difference with that of antidepressants,
when all other variables have the same values.
Chow tests are also performed to examine if the parameter estimates are significantly
different across country and therapeutic class for Equations 6 and 7. At the generation
level, the unrestricted sum of squared residuals SSR, = 8.251, and the semi-restricted sum
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of squared residuals SSRr, = 27.219. With N = 296, k = 52, and q = 36, the Chow-
statistic = 15.582, greater than the critical value of F36, 244at 5%-significance level (equals
to 1.484). Hence the null hypothesis is rejected - the Chow test shows that the there are
significant cross-country and/or cross-therapeutic-class differences in the sales of
antihypertensives and antidepressants at the generation level. A further investigation of
the regression results reveals that Japan tends to have larger absolute values for the
significant parameters for both therapeutic classes; moreover, the antihypertensive class
tends to have larger absolute values of the estimated parameters than those for the
antidepressants (comparing Tables 3.4 and 4.3).
Similarly for the share of new medication regressions, the unrestricted sum of squared
residuals SSRU = 0.705, and the semi-restricted sum of squared residuals SSRsr = 7.409, N
= 117, k = 36, and q = 25; thus the Chow-statistic = 30.821 > 1.615, the critical value of
F25, 81 at 5%-significance level. Again, the null hypothesis is rejected. Hence there are
significant cross-country and/or cross-therapeutic-class differences in the sales of new
antihypertensives and new antidepressants at generation level. In this case, most of the
significant parameter estimates are quite different for the two countries for both
therapeutic classes.
5.
Regression results of Equation 6 (dependent variable: gen_pd_capita)
Variable
Intercept
log_income_lKcapita
log_phys_lMpop
pctO_14
pct65p
time
price_ratio
price_gen
num_new_compound
new
middle
timenew
timemiddle
Germany
antihypertensives
gen_detail_capita_lag 1
gen_detail_capita_lag4*
Number of observations
Adjusted R-square
Parameter estimate
0.043
(2.87)
-0.0013
(-3.27)
0.0000014
(0.74)
-0.022
(-0.40)
-0.098
(-3.13)
0.00016
(4.34)
-0.00028
(-2.23)
0.0052
(14.22)
0.00013
(1.97)
-0.0090
(-13.81)
-0.011
(-13.98)
0.000043
(3.23)
0.00019
(8.24)
-0.0014
(-0.55)
0.0069
(23.37)
-518.52
(-15.56)
-142.42
(-7.52)
296
0.898
t-values are shown in the parenthesis below the parameter estimates.
*model is run with rel_detail_lagl replaced by rel_detail_lag4
Omitted generation variables: old, Japan, antidepressants
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Table 5. 2
Regression results of Equation 7 (dependent variable: sharenew_pd)
Variable
Intercept
income_l Kcapita
phys_lMpop
pctO_14
pct65p
time
price_ratio
share_num_newcmpnd
Germany
antihypertensives
rel_detail_lag 1
rel_detail_lag4*
Number of observations
Adjusted R-square
Parameter estimate
-2.82
(-4.57)
0.0085
(0.57)
-0.000025
(-0.34)
10.19
(4.52)
8.35
(6.29)
0.0047
(3.35)
-0.037
(-7.61)
-0.67
(-5.13)
0.021
(0.22)
-0.24
(-12.43)
-0.0057
(-2.58)
-0.000090
(-0.14)
117
0.930
t-values are shown in the parenthesis below the parameter estimates.
*model is run with log_rel_detail_lagl replaced by log_rel_detail_lag4
.
Table 5. 3
5.1.3 Product-level regression
The regression results in Tables 5.1-5.3 have all shown significant cross-therapeutic-class
difference. However, the cross-country difference is significant at the aggregated level
(the therapeutic class level) and insignificant at the disaggregated level (the generation
level). This is true for a finer disaggregated level - the product level. Table 5.4 presents
the product-level regression results (based on the logarithm form of Equation 8 in chapter
2) for the two classes of medications in the German and Japanese markets. (Detailed
SAS outputs are listed in Appendix 5.)
The parameter estimate for the antihypertensive therapeutic class dummy variable is 0.71
and significant. This value means that given other things equal, the antihypertensives are
utilized (in logarithm per-capita form) 0.71 more than the antidepressants. The country
dummy "Germany" is still insignificant, indicating an unclear cross-country difference of
the sales of the two medications, with all other parameters being the same.
Finally, a Chow test is used to check if there are statistically significant differences in the
parameter estimates across country and across therapeutic class at the product level. In
this case the unrestricted sum of squared residuals SSRU = 141718.47, and the semi-
restricted sum of squared residuals SSRsr = 149019.00. With N = 22017, k = 48, and q =
33, the Chow-statistic = 34.294. The Chow-statistic follows an F-distribution with
degrees of freedom 33 and 21969, with critical value at 5%-significance level equal to
1.390. Since the calculated Chow-statistic is greater than the critical value of F33,21969, the
null hypothesis is rejected. This means that the there are significant cross-country and/or
cross-therapeutic-class differences in the sales of antihypertensives and antidepressants at
the product level. Tables 3.6 and 4.5 show that the rejection of the Chow-test could be a
result of both cross-country and cross-class differences. For example, the log_price_prod
variable has estimated parameters with opposite signs for the antidepressants in Germany
and Japan, and also for the two therapeutic classes in Japan.
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Regression results of Equation 8 (dependent variable:
log.prod_pd_capita)
Variable
Intercept
logincome_l Kcapita
log_phys_lMpop
pct0_14
pct65p
time
log_price_prod
log_num_new compound
generic
new
middle
oldgen
Germany
antihypertensives
log_prod_detail_capita_lag 1
log_prod_detail_capita_lag4*
Number of observations
Adjusted R-square
Parameter estimate
34.98
(3.23)
-2.59
(-1.00)
1.21
(0.77)
-201.76
(-10.94)
-110.69
(-9.33)
-0.015
(-1.56)
-0.41
(-15.50)
-0.026
(-2.42)
-0.55
(-6.16)
0.98
(11.21)
0.59
(10.98)
0.25
(2.52)
-0.18
(-0.23)
0.71
(16.17)
-0.026
(-8.40)
10.48
(9.52)
22017
0.057
t-values are shown in the parenthesis below the parameter estimates.
*model is run with log_rel_detail_lagl4 replaced by log_rel_detail_lag4
Omitted generation variable: old
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Table 5. 4
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5.2 Conclusion
As stated in chapter 1, the purpose of this study has been to examine the diffusion of
antihypertensive and antidepressant medications in Germany and Japan between the first
quarter of 1992 and the last quarter of 2003. Particularly, the questions of interest are:
How do demographic, economic, cultural and health care system factors affect diffusion?
What is the role of promotion? Do pharmaceuticals diffuse differently within and across
countries and therapeutic classes? What are the health care policy implications? These
questions have been qualitatively and quantitatively addressed in chapters 3, 4 and the
first half of this chapter. In this final section, I summarize the findings regarding the
above issues.
Overall markets
Firstly, the overall German and the Japanese antihypertensive and antidepressant markets
have exhibited both the effects of government interventions and a competitive market.
Specially, Germany appears to be a more competition-driven market than Japan, in terms
of the variety of products in the market, the price elasticity, the effects of detailing, and
the adoption of generic drugs. At the aggregated class-level, the markets expanded over
time in terms of volume (patient days) and revenue (US$) for both medication classes.
However, as compared to the antihypertensive market, the non-economic factors (such as
culture and government intervention) appeared to have played a more important role in
the sales of antidepressant in Japan. This is represented by the two stages of the sales of
antidepressants in Japan, as a result of traditions and educational campaigns conducted by
the pharmaceutical industry and the government.
Secondly, there is a significant difference in the volume of sales among the three
generations (new < old). For both the antihypertensives and antidepressants, in Germany
the new generation has consisted of a greater number of compounds and was launched
earlier than that in Japan, but penetrated the antihypertensive market more slowly than
that in Japan. This reflects a German market that is more mature and competitive. In
addition, the rapid increase in and higher share of the new generation in Japan have
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resulted in a higher average price than that in Germany. Although Japan had fewer
compounds in the market (only two new antidepressant compounds), the number of new
compounds showed a positive and significant correlation with the generation-level patient
day sales in both markets.
Lastly, there is a difference in the use of branded drugs versus the generic drugs. In
general, generic drugs are used more in Germany than in Japan. The branded
antihypertensives are used more than the generics, particularly in Japan. (Remember that
the old-generation generics are used more than the new- and middle-generation generics
in the German market.) This is also true for the antidepressants in Japan. However, in
Germany the generic antihypertensives are used more than the branded drugs.
Demographic, economic and cultural factors
The age structure of the population reveals different patterns for the two countries. Two
variables that represent the age composition of the population (pctO_14 and pct65p) are
used in the econometric analysis. These variables have negative and significant
parameters in the product-level regressions for both the antihypertensives and the
antidepressants in Germany. This suggests that the middle-aged population (between 15
and 65 years old) in Germany consume more antihypertensives and antidepressants,
despite the fact that the prevalence of some condition such as hypertension is age-related
- older people are more likely to have hypertension. However, this is not the same for
Japan. The parameter estimates are not significant for the Japanese market for both
medications in the product-level regression.
The economic factor annual GDP per thousand-population (income_lKcapita) is
insignificant in most of the regressions, or has inconsistent signs of parameters in the
other regressions. This may suggest that under the health care systems of Germany and
Japan, the sales of the medications are not (or not closely) related to national income.
Cultural factors were analyzed in chapters 3 and 4 qualitatively. As mentioned earlier in
this section and in chapters 3 and 4, not only the prevalence of hypertension and
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depression but also the relative sales of the medications is closely related to the cultures
of the countries. The main cultural factors are: the composition of food intake, life styles,
as well as the public's and medical professionals' understanding of the condition and
treatments. In this study, the antidepressant market in Japan appeared to be most affected
by cultural factors.
Role of promotion
Across the two therapeutic classes, the detailing activities for antidepressants have less
significant impact on the sales of new drugs in Germany and Japan than on
antihypertensives. In some regressions such as the new antihypertensives, the promotion
variables (new-to-old relative counts of detailing) have positive and significant parameter
estimates. However, the role of the detailing activities is not consistent across country
and therapeutic classes. The detailing variables were insignificant in the regression of the
sales of the new antidepressants in Japan. In addition, the detailing effects are not very
clear for mixed new, middle and old generations at all levels (class, generation, and
product) for the two countries. The reason for the insignificant parameters in the new-
generation regressions is probably the low number of available observations as compared
to the number of explanatory variables. The reason for the unclear results of mixed-
generation regressions is that some of the older drugs were able to maintain relatively
high levels of sales volume but had low detailing efforts. (In Germany free samples,
which is part of the detailing, are not allowed to be distributed to physicians after one
year following launch, according to the pharmaceutical industry practice code [37].) On
the other hand, some new drugs are heavily promoted but have not reached a high market
share.
Cross-country and cross-therapeutic-class difference
The regressions with country dummies (Equations 5 - 8) have shown that at the
therapeutic class level, Germany has more sales of both medications (in number of
patient days per capita). However at more disaggregated levels (generation and product
level) the cross-country difference in the intercepts of the regression is not significant.
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The cross-therapeutic-class analyses have consistent regression results at all levels.
Antihypertensives were sold more than antidepressant medications when all generations
are included in one equation, while the new-generation antidepressants were sold in
greater amounts than the new-generation antihypertensives.
The Chow tests show that at all levels the parameter estimates in the regression models
have significant cross-country/class differences, as was discussed in section 5.1. This
means that at least some of the demand elasticities of the demographic, economic and
health care system factors are different in Germany and Japan, or different for
antihypertensive and antidepressants medications, or both.
Health care system factors
As discussed in chapter 1 where the two health care systems were compared, there are
stringent price controls in Germany and Japan. In both countries, price controls and
competition have led the prices of medications that have existed in the market for a
certain time to decrease and converge over time (illustrated by the new-generation
antihypertensives and antidepressants). However, the total expenditures on
antihypertensives and antidepressants per patient day (i.e., average price levels) are
different between the two countries. In general, Japan tended to have higher average
prices than Germany, since the shares of the more expensive new drugs and branded
drugs were higher. This case is especially illustrated by the antidepressant market. In the
first eight years (1992-1999) the prices of antidepressants are at similar levels in the two
countries. Since the launch of the two new compounds, the average price level in Japan
has rapidly exceeded that in Germany.
In the logarithmic form regressions, the price variables did not have very significant
parameters at the aggregated class and generation levels. At the product level, the price
variables were significant for both therapeutic classes and countries. However, for
antihypertensives the price elasticities are small and negative for Germany and Japan;
while for the antidepressants the price elasticity estimate is positive for Japan. The
negative price elasticities tell us that although the price is regulated the health care
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systems in these countries have also provided mechanisms that to some extent allow
competition. The low price elasticity demonstrates that under the social-based health
care systems, where the out-of-pocket payment is low, the demand for pharmaceuticals is
relatively price inelastic. The positive sign of the price elasticity for the antidepressant
market in Japan reflects an influential effect of the cultural and non-price health care
policy factors. As stated in chapter 4, industry and the Japanese government both
launched education campaigns, which have enhanced the awareness and thus sales of
antidepressants.
The number-of-physicians variable in the regression either was insignificant or had
negative signs. This tells us that the sales of pharmaceuticals (at least antihypertensives
and antidepressants) do not have a clear relationship with the density of the physicians
who prescribe them. The possible reasons are: firstly, both countries are developed and
the supply of the physicians is sufficient; secondly, although in Germany the physicians
have financial incentives to have as many patients as possible, they have much less
incentive to prescribe as much medications as possible, because of the way their
compensation is calculated. (For example, although the compensation is fee-for-service
based, German physicians are limited by health care policies to expand the number of
their patients [1].) Thirdly, although there are certain amounts of untreated patients who
have hypertension and depression, the causation of the lack of treatment is more likely to
be cultural reasons rather than the (in)sufficiency of physicians. Thus the fluctuations of
the number of physicians did not influence much of the actual sales of the medications.
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Appendix 1: List of antihypertensive compounds
Table Al. 1 List of antihypertensive compounds
New generation Middle generation Old generation
CANDESARTAN ALACEPRIL ACEBUTOLOL DILTIAZEM
CILEXETIL BENAZEPRIL ALPRENOLOL EFONIDIPINE
EPROSARTAN CAPTOPRIL AMLODIPINE ESMOLOL
IRBESARTAN CILAZAPRIL AMOSULALOL FELODIPINE
LOSARTAN DELAPRIL ARANIDIPINE FENDILINE
OLMESARTAN ENALAPRIL AROTINOLOL GALLOPAMIL
MEDOXOMIL FOSINOPRIL ATENOLOL INDENOLOL
TELMISARTAN IMIDAPRIL AZELNIDIPINE ISRADIPINE
VALSARTAN LISINOPRIL BARNIDIPINE LABETALOL
MOEXIPRIL BENIDIPINE LACIDIPINE
PERINDOPRIL BEPRIDIL LANDIOLOL
QUINAPRIL BETAXOLOL LERCANIDIPINE
RAMIPRIL BEVANTOLOL MANIDIPINE
SPIRAPRIL BISOPROLOL MEPINDOLOL
TEMOCAPRIL BOPINDOLOL METOPROLOL
TRANDOLAPRIL BUFETOLOL MIBEFRADIL
BUNITROLOL NADOLOL
BUPRANOLOL NEBIVOLOL
CARTEOLOL NICARDIPINE
CARVEDILOL NIFEDIPINE
CELIPROLOL NILVADIPINE
CILNIDIPINE NIPRADILOL
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Appendix 2: SAS outputs of the regression results in
chapter 3
Table A2. 1 SAS output of Table 3.3
With detailing variable lagged 1 quarter
Log-log regression for antihypertensives in Germany
The REG Procedure
Model: MODEL1
Dependent Variable: log_totpdcapita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square FValue Pr > F
Model
Error
Corrected Total
9 1.20580
23 0.06240
32 1.26820
0.13398
0.00271
49.38 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
log_income_lKcapit
logphys_lMpop
pctO_14
pct65p
time
Intercept
a
pctO_14
pct65p
Q1 1992 = 1
logprice_class
log_price_ratio
log_num_compound
log_tot_detail_capita_lag l
1 6.58809
1 0.66758
1 -1.47400
1 10.12708
1 5.30924
1 0.02996
1 0.13197
1 -0.17280
1 -0.70807
1 0.12739
96
0.05209
-4.30568
-1.20977
R-Square
Adj R-Sq
0.9508
0.9315
Variable Label
20.46892
2.95160
2.36512
54.15775
36.99520
0.00972
0.19345
0.41633
0.51965
0.09732
0.32
0.23
-0.62
0.19
0.14
3.08
0.68
-0.42
-1.36
1.31
0.7505
0.8231
0.5393
0.8533
0.8871
0.0053
0.5019
0.6820
0.1862
0.2035
With detailing variable lagged 4 quarters
Log-log regression for antihypertensives in Germany
The REG Procedure
Model: MODEL1
Dependent Variable: log_tot_pd_capita
Analysis of Variance
Sum of
DF SquaresSource
Mean
Square F Value
Model
Error
Corrected Total
9 1.20277
23 0.06543
32 1.26820
0.13364
0.00284
46.98 <.0001
Root MSE
Dependent Mean
Coeff Var
0.05334
-4.30568
-1.23874
R-Square
Adj R-Sq
0.9484
0.9282
Parameter Estimates
Variable Label
Parameter Standard
DF Estimate Error t Value
Intercept Intercept 1 9.75084
log_income_lKcapita 1 0.85256
log_phys_lMpop 1 -2.13039
pctO_14 pctO_14 1 14.55507
pct65p pct65p 1 6.61866
time Q1 1992 = 1 0.03049
logprice_class 1 0.13317
logprice_ratio 1 -0.10366
log_num_compound 1 -0.61101
log_tot_detail_capita_lag4 1 0.12609
23.94184
3.20582
2.77119
56.06354
38.82520
0.00994
0.20860
0.43630
0.55442
0.16686
97
Pr> F
Pr > Itl
0.6876
0.7927
0.4499
0.7975
0.8661
0.0055
0.5295
0.8143
0.2818
0.4575
0.41
0.27
-0.77
0.26
0.17
3.07
0.64
-0.24
-1.10
0.76
With detailing variable lagged 1 quarter
Log-log regression for antihypertensives in Japan
The REG Procedure
Model: MODEL1
Dependent Variable: log_tot_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value
Model
Error
Corrected Total
9 0.37664
12 0.03383
21 0.41048
0.04185
0.00282
14.84 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Variable Label
Parameter Standard
DF Estimate Error
Intercept Intercept 1 25.32019
log_income_lKcapita 1 -4.72632
log_phys_lMpop 1 -3.72809
log_pctO_14 1 -0.15322
log_pct65p 1 -6.19609
time Q1 1992 = 1 1 0.07468
log_price_class 1 -0.20342
log_price_ratio 1 -0.81198
log_num_compound 1 -0.19040
log_tot detail_capita_lagl 1 -0.08274
43.60516
5.49197
3.05330
4.42297
2.81478
0.01437
0.34021
1.17741
1.16475
0.25772
tValue Pr > Itl
0.58
-0.86
-1.22
-0.03
-2.20
5.20
-0.60
-0.69
-0.16
-0.32
0.5722
0.4063
0.2455
0.9729
0.0480
0.0002
0.5610
0.5035
0.8729
0.7537
98
Pr> F
0.05310
-4.38710
-1.21032
R-Square
Adj R-Sq
0.9176
0.8558
With detailing variable lagged 4 quarters
Log-log regression for antihypertensives in Japan
The REG Procedure
Model: MODEL1
Dependent Variable: log_tot_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value
Model
Error
Corrected Total
9 0.37844
12 0.03204
21 0.41048
0.04205
0.00267
15.75 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Variable Label
Parameter Standard
DF Estimate Error
Intercept Intercept 1 13.66519
logincome_lKcapita 1 -4.14490
log_phys_lMpop 1 -2.10836
logpctO_14 1 1.31480
log_pct65p 1 -7.28005
time Q1 1992 = 1 1 0.07766
logprice_class 1 -0.47690
log_price_ratio 1 -0.59411
log_num_compound 1 -0.03511
log_tot_detail_capita_lag4 1 0.18229
33.26574
3.46030
3.05083
4.55082
2.40129
0.01376
0.46659
1.17450
1.09283
0.20617
tValue Pr > It
0.41
-1.20
-0.69
0.29
-3.03
5.64
-1.02
-0.51
-0.03
0.88
0.6885
0.2541
0.5027
0.7776
0.0104
0.0001
0.3269
0.6221
0.9749
0.3940
99
Pr> F
0.05167
-4.38710
-1.17776
R-Square
Adj R-Sq
0.9220
0.8634
Table A2. 2 SAS output of Table 3.4
With detailing variable lagged 1 quarter
Log-log regression for antihypertensives in Germany
Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_gen_pd_capita
Analysis of Variance
Sum of
DF SquaresSource
Mean
Square F Value Pr > F
Model
Error
Corrected Total
13 170.12330
85 6.09631
98 176.21961
13.08641
0.07172
182.46 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Label
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
log_income_lKcapita
log_phys_lMpop
pctO_14
pct65p
time
logprice_ratio
logprice_gen
log_num_new_compc
log_gendetail_capita
new
middle
timenew
timemiddle
Intercept 1
1
1
pctO_14 1
pct65p 1
Q1 1992 = 1
1
1
ound 1
Llagl 1
1
1
1
1
0.26781
-5.94041
-4.50825
R-Square
Adj R-Sq
0.9654
0.9601
Variable
-43.55080
-3.50578
3.75293
44.20788
42.02033
-0.01600
-1.17295
-0.78032
0.31764
-0.46143
-4.73896
-2.36035
0.09309
0.04771
54.07925
8.14663
6.48608
127.56665
90.35808
0.03040
1.24101
0.43386
0.14186
0.11041
0.37562
0.41603
0.00828
0.01224
-0.81
-0.43
0.58
0.35
0.47
-0.53
-0.95
-1.80
2.24
-4.18
-12.62
-5.67
11.24
3.90
0.4229
0.6680
0.5644
0.7298
0.6431
0.6000
0.3473
0.0756
0.0278
<.0001
<.0001
<.0001
<.0001
0.0002
100
With detailing variable lagged 4 quarters
Log-log regression for antihypertensives in Germany
Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_gen_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
13 169.51387
85 6.70575
98 176.21961
13.03953
0.07889
165.29 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Label
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
log_incomelKcapit
log_phys_lMpop
pctO_14
pct65p
time
logprice_ratio
logprice_gen
log_num_newcoml
log_gendetail_capi
new
middle
timenew
timemiddle
Intercept 1 -40.75342
ta 1 -7.06680
1 4.74759
pctO_14 1 36.74112
pct65p 1 28.27575
Q1 1992 = 1 1 0.01242
1 -0.72086
1 -0.55169
pound 1 0.14939
ita_lag4 1 -0.80924
1 -4.84192
1 -1.37119
1 0.08389
1 0.01815
101
0.28088
-5.94041
-4.72822
R-Square
Adj R-Sq
0.9619
0.9561
Variable
57.28322
8.65372
6.85184
134.57944
94.89868
0.03096
1.31860
0.44834
0.14664
0.28339
0.39358
0.31641
0.00833
0.00905
-0.71
-0.82
0.69
0.27
0.30
0.40
-0.55
-1.23
1.02
-2.86
-12.30
-4.33
10.07
2.01
0.4788
0.4164
0.4903
0.7855
0.7665
0.6893
0.5860
0.2219
0.3112
0.0054
<.0001
<.0001
<.0001
0.0481
With detailing variable lagged 1 quarter
Log-log regression for antihypertensives in Japan
Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_gen_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square FValue Pr > F
Model
Error
Corrected Total
13 95.14661
52 1.20173
65 96.34835
7.31897
0.02311
316.70 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Label
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept Intercept 1 28.59710
log_income_1Kcapita 1 6.81952
log_phys_lMpop 1 -5.89238
pctO_14 pctO14 1 -68.29084
pct65p pct65p 1 -45.56261
time Q1 1992= 1 1 -0.01599
logprice_ratio 1 -1.59180
logprice_gen 1 0.44094
log_num _new_compound 1 0.42955
log_gen_detail_capita_lagl 1 -0.78006
new 1 -9.27632
middle 1 -3.94499
timenew 1 0.18828
timemiddle 1 0.07158
102
0.15202
-5.98423
-2.54036
R-Square
Adj R-Sq
0.9875
0.9844
Variable
41.38113
4.77000
5.19685
47.11902
19.31144
0.02459
1.81708
0.52538
0.14748
0.14947
0.62160
0.68945
0.00886
0.01888
0.69
1.43
-1.13
-1.45
-2.36
-0.65
-0.88
0.84
2.91
-5.22
-14.92
-5.72
21.25
3.79
0.4926
0.1588
0.2621
0.1533
0.0221
0.5182
0.3850
0.4052
0.0053
<.0001
<.0001
<.0001
<.0001
0.0004
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With detailing variable lagged 4 quarters
Log-log regression for antihypertensives in Japan
Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_gen_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
13 94.60874
52 1.73961
65 96.34835
7.27760
0.03345
217.54 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Label
Parameter Standard
DF Estimate Error tValue Pr> Itl
Intercept Intercept 1 63.91913
log_income_lKcapita 1 -0.60861
logphys_lMpop 1 -8.29021
pctO_14 pctO_14 1 -52.20628
pct65p pct65p 1 -43.54128
time Q1 1992 = 1 0.05137
log_price_ratio 1 0.43284
logprice_gen 1 -0.14112
log_num_new_compound 1 0.25056
log_gen_detail_capita_lag4 1 -0.85610
new 1 -8.32644
middle 1 -1.11468
timenew 1 0.16403
timemiddle 1 -0.00468
103
0.18290
-5.98423
-3.05644
R-Square
Adj R-Sq
0.9819
0.9774
Variable
57.69288
9.02063
6.67860
59.38093
25.08703
0.03082
2.31354
0.69886
0.18715
0.51756
0.86366
0.43928
0.01012
0.01247
1.11
-0.07
-1.24
-0.88
-1.74
1.67
0.19
-0.20
1.34
-1.65
-9.64
-2.54
16.20
-0.38
0.2730
0.9465
0.2201
0.3834
0.0886
0.1016
0.8523
0.8408
0.1865
0.1041
<.0001
0.0142
<.0001
0.7090
Table A2. 3 SAS output of Table 3.5
With detailing variable lagged 1 quarter
Log-log regression for antihypertensives in Germany
The REG Procedure
Model: MODEL1
Dependent Variable: log_share_new_pd
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
8 16.08525
23 0.40503
31 16.49028
2.01066
0.01761
114.18 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept Intercept
log_incomelKcapita
log_phys_lMpop
pctO_14 pctO_14
pct65p pct65p
time Q1 1992 = 1
log_price_ratio
share_num_newcmpnd
Iog_rel_detail_lagl
1 99.73688
1 -10.14717
1 3.85131
1 -376.91743
1 -274.45458
1 0.05240
1 0.00089835
1 9.87276
1 0.23975
104
0.13270
-3.14615
-4.21792
R-Square
Adj R-Sq
0.9754
0.9669
Variable Label
43.62016
6.65668
6.05325
121.81338
82.36994
0.02341
1.18877
2.44535
0.11528
2.29
-1.52
0.64
-3.09
-3.33
2.24
0.00
4.04
2.08
0.0318
0.1411
0.5309
0.0051
0.0029
0.0352
0.9994
0.0005
0.0489
___ __ ___ 
With detailing variable lagged 4 quarters
Log-log regression for antihypertensives in Germany
The REG Procedure
Model: MODEL1
Dependent Variable: log_share_new_pd
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
8 16.35644
23 0.13383
31 16.49028
2.04456
0.00582
351.36 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error tValue Pr > Itl
Intercept Intercept
logincome_lKcapita
log_phys_lMpop
pctO_14 pctO_14
pct65p pct65p
time Q1 1992 = 1
logprice_ratio
share_num_newcmpnd
log_reldetaillag4
1 21.98112
1 -6.78810
1 6.14784
1 -200.60574
1 -136.50871
1 0.01848
1 -0.67686
1 6.26350
1 0.45274
0.07628
-3.14615
-2.42461
R-Square
Adj R-Sq
0.9919
0.9891
Variable Label
26.40635
3.83658
3.09993
72.56170
50.83992
0.01417
0.68694
1.47913
0.05860
0.83
-1.77
1.98
-2.76
-2.69
1.30
-0.99
4.23
7.73
0.4137
0.0901
0.0594
0.0110
0.0132
0.2050
0.3347
0.0003
<.0001
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With detailing variable lagged 1 quarter
Log-log regression for antihypertensives in Japan
The REG Procedure
Model: MODEL1
Dependent Variable: log_share_new_pd
Analysis of Variance
Sum of
DF SquaresSource
Mean
Square F Value Pr > F
Model
Error
Corrected Total
8 18.49516
12 0.17141
20 18.66657
2.31189
0.01428
161.85 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error tValue Pr > Itl
Intercept Intercept
logincome_lKcapita
log_phys_lMpop
pctO_14 pctO_14
pct65p pct65p
time Q 19
logprice_ratio
share_num_newcmpnd
log_rel_detail_lagl
192 = 1
1
1
1
1
1
1
1
1
1
-17.50589
27.06616
-5.02998
-168.13973
-79.58810
0.08899
3.23475
13.95853
0.62016
106
0.11952
-2.63746
-4.53151
R-Square
Adj R-Sq
0.9908
0.9847
Variable Label
49.05177
8.61271
6.78552
76.28644
26.20509
0.03423
4.28385
6.36812
0.19902
-0.36
3.14
-0.74
-2.20
-3.04
2.60
0.76
2.19
3.12
0.7274
0.0085
0.4728
0.0478
0.0103
0.0232
0.4647
0.0488
0.0089
With detailing variable lagged 4 quarters
Log-log regression for antihypertensives in Japan
The REG Procedure
Model: MODEL1
Dependent Variable: log_sharenew_pd
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
8 18.63141
12 0.03515
20 18.66657
2.32893
0.00293
795.00 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error t Value Pr > lt
Intercept Intercept
log_income_lKcapita
log_phys_lMpop
pctO_14 pctO_1,
pct65p pct65p
time Q1 199
log_price_ratio
share_num_newcmpnd
logreldetail_lag4
4
2 = 1
1 -65.58020
1 11.59543
1 4.80391
1 -38.39929
1 -37.69159
1 0.04189
1 -0.20622
1 10.63009
1 0.58132
107
0.05412
-2.63746
-2.05215
R-Square
Adj R-Sq
0.9981
0.9969
Variable Label
22.91945
4.50149
3.37144
39.41107
13.14405
0.01694
2.00398
2.92488
0.06000
-2.86
2.58
1.42
-0.97
-2.87
2.47
-0.10
3.63
9.69
0.0143
0.0243
0.1797
0.3491
0.0142
0.0294
0.9197
0.0034
<.0001
Table A2. 4 SAS output of Table 3.6
With detailing variable lagged 1 quarter
Log-log regression for antihypertensives in Germany
Omitted drug type: branded; Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_prod_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Model
Error
Corrected Total
Root MSE
Dependent Mean
Coeff Var
12
12377
12389
4766.10527
77202
81968
Mean
Square
397.17544
6.23752
FValue Pr > F
63.68 <.0001
2.49750 R-Square 0.0581
-12.09900 Adj R-Sq 0.0572
-20.64223
Parameter Estimates
Parameter Standard
DF Estimate Error t Value Pr> tl
Intercept
log_income_lKcapita
log_phys_lMpop
pct0_14
pct65p
Interca
pct0_1
pct651
time Q1 199;
log_price_prod
log_num_new_compound
log_prod_detail_capita_lag 1
generic
new
middle
oldgen
ept 1
1
1
4 1
p 1
2:1 1
1
1
1
1
1
1
1
49.65332
-5.85408
1.67296
-227.45407
-135.22230
-0.00740
-0.60180
-0.01079
-0.01606
-0.71455
1.86797
1.03528
0.39332
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Variable Label
15.61195
4.11692
2.69596
48.84605
33.64257
0.01297
0.03639
0.01461
0.00395
0.11010
0.17194
0.06281
0.12239
3.18
-1.42
0.62
-4.66
-4.02
-0.57
-16.54
-0.74
-4.07
-6.49
10.86
16.48
3.21
0.0015
0.1551
0.5349
<.0001
<.0001
0.5681
<.0001
0.4603
<.0001
<.0001
<.0001
<.0001
0.0013
___ _ ____
With detailing variable lagged 4 quarters
Log-log regression for antihypertensives in Germany
Omitted drug type: branded; Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_prod_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Model
Error
Corrected Total
12
15959
15971
8009.32653
106039
114049
Root MSE 2.57769
Dependent Mean -12.43637
Coeff Var -20.72703
Parameter Estimates
Mean
Square
667.44388
6.64449
R-Square
Adj R-Sq
F Value Pr > F
100.45 <.0001
0.0702
0.0695
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
logincomelKcapil
log.physlMpop
pctO_14
pct65p
time
logprice_prod
lognumnew_com
logprod detailcar
generic
new
middle
oldgen
Intercept 1 35.79596
ta 1 -6.15665
1 2.02929
pctO014 1 -186.48696
pct65p 1 -108.41577
Q1 1992 = 1 1 -0.01226
1 -0.76312
pound 1 -0.01008
pita_lag4 1 -0.06242
1 -0.50843
1 1.13680
1 1.00358
1 0.22363
109
Variable Label
18.67339
5.92927
4.76739
51.21838
35.46508
0.01296
0.03362
0.01360
0.00487
0.10909
0.13319
0.05816
0.11986
1.92
-1.04
0.43
-3.64
-3.06
-0.95
-22.70
-0.74
-12.82
-4.66
8.54
17.26
1.87
0.0553
0.2991
0.6704
0.0003
0.0022
0.3440
<.0001
0.4584
<.0001
<.0001
<.0001
<.0001
0.0621
With detailing variable lagged 1 quarter
Log-log regression for antihypertensives in Japan
Omitted drug type: branded; Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_prod_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Model 12
Error 3205
Corrected Total 3217
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
4677.81948
27620
32297
2.93558
-12.36091
-23.74890
Mean
Square F
389.81829
8.61764
R-Square
Adj R-Sq
Value Pr > F
45.23 <.0001
0.1448
0.1416
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept InterceF
log_income_lKcapita
log_physLMpop
pctO_14 pctO_14
pct65p pct65p
time Q1 1992
log_price_prod
log_num_new_compound
log_prod_detail_capita_lag 1
generic
new
middle
oldgen
)t 1 82.91347
1 -30.96404
1 -0.52221
1 35.70880
1 19.10362
= 1 1 -0.06080
1 -0.15112
1 0.02678
1 -0.04318
1 -2.50215
1 4.36729
1 -0.47101
1 -0.39031
110
Variable Label
72.67320
10.75405
8.72172
98.67018
46.68294
0.05012
0.05749
0.05047
0.00953
0.35346
0.39351
0.11821
0.41829
1.14
-2.88
-0.06
0.36
0.41
-1.21
-2.63
0.53
-4.53
-7.08
11.10
-3.98
-0.93
0.2540
0.0040
0.9523
0.7175
0.6824
0.2252
0.0086
0.5957
<.0001
<.0001
<.0001
<.0001
0.3508
--111111111--
With detailing variable lagged 4 quarters
Log-log regression for antihypertensives in Japan
Omitted drug type: branded; Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_prod_pdcapita
Analysis of Variance
Sum of
Source DF Squares
Model
Error
Corrected Total
12
4047
4059
5561.89499
33214
38776
Root MSE 2.86479
Dependent Mean -12.56644
Coeff Var -22.79718
Parameter Estimates
Mean
Square
463.49125
8.20704
R-Square
Adj R-Sq
FValue Pr > F
56.47 <.0001
0.1434
0.1409
Variable Label
Parameter Standard
DF Estimate Error
Intercept Intercept 1 97.20588
log_income_lKcapita 1 -26.66384
log_phys_lMpop 1 -3.06886
pctO 14 pctO_14 1 -5.39162
pct65p pct65p 1 4.32520
time Q1 1992 = 1 1 -0.04971
logprice_prod 1 -0.10812
log_num_new_compound 1 0.01556
logproddetail_capita_lag4 1 0.00379
generic 1 -2.47631
new 1 4.57784
middle 1 -0.26069
oldgen 1 -0.30798
62.92745
9.05578
7.48012
82.00528
39.98995
0.04344
0.04964
0.04416
0.01048
0.28181
0.38203
0.10612
0.33131
tValue Pr > Itl
1.54
-2.94
-0.41
-0.07
0.11
-1.14
-2.18
0.35
0.36
-8.79
11.98
-2.46
-0.93
0.1225
0.0033
0.6816
0.9476
0.9139
0.2525
0.0295
0.7245
0.7172
<.0001
<.0001
0.0141
0.3526
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Appendix 3: List of antidepressant compounds
Table A3. 1 List of antihypertensive compounds
New generation Old generation
CITALOPRAM AMFETAMINIL METHYLPHENIDATE
ESCITALOPRAM AMITRIPTYLINE MIANSERIN
FLUOXETINE AMITRIPTYLINOXIDE MILNACIPRAN
FLUVOXAMINE AMOXAPINE MIRTAZAPINE
NEFAZODONE CLOMIPRAMINE MOCLOBEMIDE
PAROXETINE DESIPRAMINE NORTRIPTYLINE
REBOXETINE DIBENZEPIN OPIPRAMOL
SERTRALINE DOSULEPIN OXITRIPTAN
VENLAFAXINE DOXEPIN PEMOLINE
FENETY LLINE PIPRADROL
HYPERICUM SETIPTILINE
PERFORATUM
IMIPRAMINE TRANY LCY PROMINE
LITHIUM TRAZODONE
LOFEPRAMINE TRIMIPRAMINE
MAPROTILINE VILOXAZINE
112
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Appendix 4: SAS outputs of the regression results in
chapter 4
Table A4. 1 SAS output of Table 4.2
With detailing variable lagged 1 quarter
Log-log regression for antidepressants in Germany
The REG Procedure
Model: MODEL1
Dependent Variable: log_tot_pd_capita
Analysis of Variance
Sum of Mean
Source DF Squares Square F Value Pr > F
Model 9 3.34468 0.37163 107.85 <.0001
Error 36 0.12405 0.00345
Corrected Total 45 3.46873
Root MSE 0.05870 R-Square 0.9642
Dependent Mean -6.07228 Adj R-Sq 0.9553
Coeff Var -0.96671
Parameter Estimates
Parameter Standard
Variable Label DF Estimate Error t Value Pr > Itl
Intercept Intercept 1 30.97769 14.47857 2.14 0.0392
log_income_lKcapita 1 0.58767 1.64238 0.36 0.7226
log_phys_lMpop 1 -1.82943 1.15170 -1.59 0.1209
logpctO_14 1 8.44702 3.46390 2.44 0.0198
log_pct65p 1 6.15444 2.60951 2.36 0.0239
time Q1 1992 = 1 1 0.02583 0.00798 3.24 0.0026
logprice_class 1 0.29182 0. 14483 2.01 0.0514
logprice_ratio 1 0.71095 0.18466 3.85 0.0005
log_num_compound 1 0.65769 0.38758 1.70 0.0983
log_tot_detailcapita_lagl 1 0.08646 0.07641 1.13 0.2653
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With detailing variable lagged 4 quarters
Log-log regression for antidepressants in Germany
The REG Procedure
Model: MODEL1
Dependent Variable: logtot_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
9 2.83874
34 0.10437
43 2.94310
0.31542
0.00307
102.75 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept Inte
logincome_lKcapita
logphys_lMpop
logpctO_14
log_pct65p
time Q1 1
log_priceclass
logprice_ratio
log_num_compound
log_tot_detail_capita_lag4
rcept 1 16.75868
1 -2.67790
1 0.95360
1 7.94840
1 5.88796
.992 = 1 1 0.02434
1 0.15948
1 0.50209
1 0.80785
1 0.06939
114
0.05540
-6.04959
-0.91583
R-Square
Adj R-Sq
0.9645
0.9552
Variable Label
21.45099
2.66937
2.21860
4.14831
2.94452
0.00762
0.18240
0.16886
0.23843
0.04518
0.78
-1.00
0.43
1.92
2.00
3.20
0.87
2.97
3.39
1.54
0.4401
0.3229
0.6700
0.0638
0.0536
0.0030
0.3881
0.0054
0.0018
0.1338
_ _ __ _
With detailing variable lagged 1 quarter
Log-log regression for antidepressants in Japan
The REG Procedure
Model: MODELi
Dependent Variable: log_tot_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
9 0.53713
9 0.02121
18 0.55834
0.05968
0.00236
25.32 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Variable Label
Parameter Standard
DF Estimate Error
Intercept Intercept 1 82.54803
log_income_lKcapita 1 -10.16187
log_physlMpop 1 -9.16014
logpctO_14 1 2.75599
log_pct65p 1 -6.22885
time Q1 1992 = 1 1 0.15369
logprice_class 1 -1.14223
logprice_ratio 1 1.36992
log_num_compound 1 -0.84344
log_tot_detail_capita_lagl 1 -0.05337
47.30015
5.62924
5.47161
7.39928
3.03098
0.03311
0.54704
0.71554
0.74409
0.04186
t Value Pr > Itl
1.75
-1.81
-1.67
0.37
-2.06
4.64
-2.09
1.91
-1.13
-1.27
0.1149
0.1045
0.1284
0.7182
0.0700
0.0012
0.0664
0.0878
0.2863
0.2343
115
0.04855
-6.86870
-0.70678
R-Square
Adj R-Sq
0.9620
0.9240
With detailing variable lagged 4 quarters
Log-log regression for antidepressants in Japan
The REG Procedure
Model: MODEL1
Dependent Variable: log_totpd_capita
Analysis of Variance
Sum of
DF SquaresSource
Mean
Square F Value
Model
Error
Corrected Total
9 0.53330
9 0.02504
18 0.55834
0.05926
0.00278
21.30 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Variable Label
Parameter
DF Estimate
Intercept Intercept 1 54.46485
logincome_lKcapita 1 -9.85995
logphyslMpop 1 -5.22298
log_pctO_14 1 3.95844
log_pct65p 1 -6.44926
time Q1 1992 = 1 1 0.13611
log_priceclass 1 -0.93364
log_price_ratio 1 0.79003
log_num_compound 1 -0.32799
log_tot_detail_capita_lag4 1 0.00212
Standard
Error
47.64773
6.19669
5.32685
7.99845
3.33789
0.03340
0.56741
0.77491
0.83940
0.08246
tValue Pr> Itl
1.14
-1.59
-0.98
0.49
-1.93
4.08
-1.65
1.02
-0.39
0.03
0.2825
0.1460
0.3525
0.6325
0.0854
0.0028
0.1343
0.3346
0.7051
0.9800
116
Pr> F
0.05275
-6.86870
-0.76792
R-Square
Adj R-Sq
0.9552
0.9103
_ _
Table A4. 2 SAS output of Table 4.3
With detailing variable lagged 1 quarter
Log-log regression for antidepressants in Germany
Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_gen_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square FValue Pr > F
Model
Error
Corrected Total
11 193.18472
81 0.61981
92 193.80453
17.56225
0.00765
2295.14 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error tValue Pr> Itl
Intercept
log_income_lKcapit
logphys_lMpop
pctO_14
pct65p
time
logprice_ratio
logprice_gen
log_num_new_coml
log_gen_detail_capi
new
timenew
Intercept 1 -16.26336
:a 1 4.19641
1 -2.42840
pctO_14 1 49.51385
pct65p 1 41.90877
Q1 1992 = 1 1 -0.00644
1 0.21953
1 -0.24272
pound 1 0.39902
ita_lagl 1 -0.05339
1 -3.55628
1 0.05836
117
0.08748
-7.41323
-1.17999
R-Square
Adj R-Sq
0.9968
0.9964
Variable Label
9.05423
1.53343
1.10993
23.68285
16.36340
0.00797
0.16466
0.11309
0.07650
0.03635
0.20476
0.00253
-1.80
2.74
-2.19
2.09
2.56
-0.81
1.33
-2.15
5.22
-1.47
-17.37
23.05
0.0762
0.0076
0.0316
0.0397
0.0123
0.4216
0.1862
0.0348
<.0001
0.1458
<.0001
<.0001
With detailing variable lagged 4 quarters
Log-log regression for antidepressants in Germany
Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_gen_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
11 175.62936
76 0.42279
87 176.05215
15.96631
0.00556
2870.10 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
logincomelKcapi
logphys_lMpop
pctO_14
pct65p
time
logpriceratio
log_price_gen
log_num_new_com
log_gen_detail capi
new
timenew
Intercept 1 -30.64686
ta 1 -5.00225
1 4.87841
pctO_14 1 -6.27766
pct65p 1 5.74161
Q1 1992 = 1 1 0.00681
1 0.33221
1 -0.43680
pound 1 0.24302
ita_lag4 1 0.06281
1 -3.35247
1 0.05936
11 R
0.07459
-7.37718
-1.01103
R-Square
Adj R-Sq
0.9976
0.9973
Variable Label
8.76646
2.44612
1.93260
22.87770
15.70655
0.00723
0.13443
0.11244
0.06210
0.05238
0.21969
0.00227
-3.50
-2.04
2.52
-0.27
0.37
0.94
2.47
-3.88
3.91
1.20
-15.26
26.19
0.0008
0.0443
0.0137
0.7845
0.7157
0.3493
0.0157
0.0002
0.0002
0.2343
<.0001
<.0001
__ __
With detailing variable lagged 1 quarter
Log-log regression for antidepressants in Japan
Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_gen_pd_capita
Analysis of Variance
Source
Model
Error
Corrected Total
Sum of
DF Squares
11
26
37
16.75815
0.33275
17.09090
Mean
Square
1.52347
0.01280
FValue Pr > F
119.04 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error tValue Pr> Itl
Intercept
logincome_lKcapil
logphys_lMpop
pctO_14
pct65p
time
log_price_ratio
logprice_gen
log_num_new_com
log_gen_detail_cap
new
timenew
Intercept 1 40.18373
ta 1 -7.59246
1 -3.96417
pctO_14 1 51.81126
pct65p 1 -26.80679
Q1 1992 = 1 1 0.06972
1 0.95324
1 0.00580
pound 1 -0.04526
ita_lagl 1 0.00564
1 -4.46290
1 0.08630
119
0.11313
-7.72701
-1.46406
R-Square
Adj R-Sq
0.9805
0.9723
Variable Label
43.69777
9.99922
5.83409
94.87634
27.80115
0.02371
0.71375
0.50994
0.16027
0.09514
0.71755
0.00917
0.92
-0.76
-0.68
0.55
-0.96
2.94
1.34
0.01
-0.28
0.06
-6.22
9.41
0.3662
0.4545
0.5028
0.5897
0.3438
0.0068
0.1933
0.9910
0.7799
0.9532
<.0001
<.0001
With detailing variable lagged 4 quarters
Log-log regression for antidepressants in Japan
Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_gen_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value
Model
Error
Corrected Total
11 16.93079
26 0.16010
37 17.09090
1.53916
0.00616
249.95 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
log_income_lKcapit
log_physlMpop
pct0_14
pct65p
time
log_price_ratio
log_price_gen
log_num_new_com 
log_gendetail_capi
new
timenew
Intercept 1 -53.39801
'a 1 -8.76972
1 8.62075
pctO_14 1 124.23758
pct65p 1 -27.39800
Q1 1992 = 1 1 0.04590
1 -0.83754
1 -0.11405
pound 1 0.23803
ita_lag4 1 0.47230
1 -4.07193
1 0.08091
120
Pr > F
0.07847
-7.72701
-1.01556
R-Square
Adj R-Sq
0.9906
0.9867
Variable Label
34.87106
6.00797
4.69250
55.96355
18.25052
0.01517
0.56180
0.29437
0.11930
0.08919
0.29776
0.00623
-1.53
-1.46
1.84
2.22
-1.50
3.03
-1.49
-0.39
2.00
5.30
-13.68
12.98
0.1378
0.1564
0.0776
0.0353
0.1453
0.0055
0.1480
0.7016
0.0566
<.0001
<.0001
<.0001
Table A4. 3 SAS output of Table 4.4
With detailing variable lagged 1 quarter
Linear regression for antidepressants in Germany
The REG Procedure
Model: MODEL1
Dependent Variable: share_new_pd
Analysis of Variance
Sum of
DF SquaresSource
Mean
Square F Value Pr > F
Model
Error
Corrected Total
8 0.25288
37 0.00232
45 0.25520
0.03161
0.00006282
503.16 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error tValue Pr > Itl
Intercept IntercE
income_lKcapita
phys_lMpop
pctO_14 pctO_
pct65p pct65
time Q1 1992
price_ratio
share_num_newcmpnd
reldetail_lag1
!pt 1
1
1
.4 1
p 1
=1 1
1
1
1
1.99739
0.00500
-0.00010397
-6.33465
-4.14127
0.00709
-0.01930
-0.61066
0.01944
0.00793
0.10110
7.83982
R-Square
Adj R-Sq
0.9909
0.9889
Variable Label
0.83570
0.00876
0.00004766
3.00655
2.04727
0.0009371
0.00447
0.05836
0.00896
2.39
0.57
-2.18
-2.11
-2.02
7.57
-4.31
-10.46
2.17
0.0221
0.5717
0.0356
0.0420
0.0504
<.0001
0.0001
<.0001
0.0366
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With detailing variable lagged 4 quarters
Linear regression for antidepressants in Germany
The REG Procedure
Model: MODEL1
Dependent Variable: share_new_pd
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value
Model
Error
Corrected Total
8 0.24120
35 0.00235
43 0.24355
0.03015
0.00006713
449.10 <.0001
Root MSE
Dependent Mean
Coeff Var
0.00819
0.10449
7.84151
R-Square 0.9904
Adj R-Sq 0.9881
Parameter Estimates
Parameter Standard
DF Estimate Error tValue Pr > Itl
Intercept
income_lKcapi
phys_lMpop
pctO_14
pct65p
time
price_ratio
share_num_net
rel_detail_lag4
Intercept 1 1.47346
ta 1 0.01128
1 -0.0001444
pctO_14 1 -4.24068
pct65p 1 -3.12527
Q1 1992 = 1 0.00672
1 -0.01713
Ncmpnd 1 -0.57026
1 0.00794
Pr> F
Variable Label
1.04898
0.01654
0.00009226
3.68672
2.47112
0.00114
0.00521
0.06658
0.00405
1.40
0.68
-1.57
-1.15
-1.26
5.88
-3.29
-8.56
1.96
0.1689
0.4997
0.1266
0.2578
0.2143
<.0001
0.0023
<.0001
0.0578
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With detailing variable lagged 1 quarter
Linear regression for antidepressants in Japan
The REG Procedure
Model: MODEL1
Dependent Variable: share_new_pd
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
8 0.10074
9 0.0003291
17 0.10107
0.01259
0.00003657
344.37 <.0001
Root MSE
Dependent Mean
Coeff Var
0.00605
0.27157
2.22667
R-Square 0.9967
Adj R-Sq 0.9938
Parameter Estimates
Parameter Standard
DF Estimate Error tValue Pr > lt
Intercept Intercept
income_lKcapita
phys_lMpop
pctO_14 pctO_14
pct65p pct65p
time Q1 1992 = 1
price_ratio
share_numnewcmpnd
rel_detaillagl
1 -1.19890
1 -0.02990
1 -0.00010466
1 9.54166
1 2.28590
1 0.01590
1 -0.00428
1 -0.13707
1 -0.00342
Variable Label
0.94259
0.04101
0.00023441
8.33259
2.33404
0.00152
0.01642
0.18591
0.00203
-1.27
-0.73
-0.45
1.15
0.98
10.43
-0.26
-0.74
-1.68
0.2353
0.4846
0.6658
0.2817
0.3530
<.0001
0.8001
0.4797
0.1268
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With detailing variable lagged 4 quarters
Linear regression for antidepressants in Japan
The REG Procedure
Model: MODEL1
Dependent Variable: share_new_pd
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value
Model
Error
Corrected Total
8 0.10064
9 0.00042858
17 0.10107
0.01258 264.18
0.00004762
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
income_lKca
phys_lMpop
pctO_14
pct65p
time
price_ratio
share_num_r
rel_detaillag
Intercept 1 -0.55885
pita 1 0.02623
1 -0.00020007
pctO_14 1 -0.23213
pct65p 1 0.51539
Q1 1992 = 1 1 0.01496
1 -0.01298
iewcmpnd 1 0.00799
]4 1 -0.00017646
Pr> F
<.0001
0.00690
0.27157
2.54101
R-Square
Adj R-Sq
0.9958
0.9920
Variable Label
1.03798
0.03772
0.00026122
6.78603
2.45607
0.00171
0.02392
0.20786
0.00060880
-0.54
0.70
-0.77
-0.03
0.21
8.75
-0.54
0.04
-0.29
0.6034
0.5044
0.4633
0.9735
0.8385
<.0001
0.6007
0.9702
0.7785
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Table A4. 4 SAS output of Table 4.5
With detailing variable lagged 1 quarter
Log-log regression for Antidepressants in Germany
Omitted drug type: branded; Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_prod_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Model
Error
Corrected Total
10
5728
5738
1293.44365
34620
35914
Root MSE 2.45846
Dependent Mean -13.18949
Coeff Var -18.63957
Parameter Estimates
Mean
Square
129.34436
6.04404
R-Square
Adj R-Sq
F Value Pr > F
21.40 <.0001
0.0360
0.0343
Parameter Standard
DF Estimate Error tValue Pr > Itl
Intercept
log_income_lKcapita
log_phys_lMpop
pctO_14
pct65p
time Q1
logprice_prod
log_num_newcompol
logprod_detail_capitz
generic
new
Intercept 1 27.13772
1 -6.22941
1 4.81227
pctO_14 1 -254.89713
pct65p 1 -122.05771
1 1992 = 1 1 -0.03263
1 -0.23616
und 1 0.25835
alag 1 -0.04042
1 0.31902
1 0.19530
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Variable Label
21.62814
5.90824
4.11386
79.97294
53.86337
0.01900
0.05796
0.20300
0.00546
0.07273
0.11683
1.25
-1.05
1.17
-3.19
-2.27
-1.72
-4.07
1.27
-7.41
4.39
1.67
0.2096
0.2918
0.2421
0.0014
0.0235
0.0859
<.0001
0.2032
<.0001
<.0001
0.0946
With detailing variable lagged 4 quarters
Log-log regression for Antidepressants in Germany
Omitted drug type: branded; Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_prod_pdcapita
Analysis of Variance
Sum of
Source DF Squares
Model
Error
Corrected Total
10
8257
8267
1635.99703
51480
53116
Root MSE 2.49694
Dependent Mean -13.39929
Coeff Var -18.63484
Parameter Estimates
Mean
Square
163.59970
6.23469
R-Square
Adj R-Sq
F Value Pr > F
26.24 <.0001
0.0308
0.0296
Parameter
DF Estimate
Standard
Error tValue Pr> Itl
Intercept
logincome_lKcapita
log_phys_lMpop
pctO_14
pct65p
time q
log_price_prod
log_num_new_compoi
log_prod_detail_capit
generic
new
Intercept 1 -21.70602
1 -18.78735
1 17.34228
pct_14 1 -303.36185
pct65p 1 -156.97820
21 1992 = 1 1 -0.02132
1 -0.49767
und 1 0.24033
ilag4 1 -0.01571
1 0.30784
1 0.46261
126
Variable Label
23.79342
8.14979
6.58389
75.73472
51.65706
0.01773
0.04646
0.17085
0.00627
0.06306
0.09611
-0.91
-2.31
2.63
-4.01
-3.04
-1.20
-10.71
1.41
-2.50
4.88
4.81
0.3617
0.0212
0.0085
<.0001
0.0024
0.2291
<.0001
0.1596
0.0123
<.0001
<.0001
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With detailing variable lagged 1 quarter
Log-log regression for Antidepressants in Japan
Omitted drug type: branded; Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: log_prod_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Model 10
Error 659
Corrected Total 669
Root MSE
Dependent Mean
Coeff Var
436.00581
2276.47085
2712.47666
1.85861
-11.52305
-16.12949
Mean
Square
43.60058
3.45443
R-Square
Adj R-Sq
FValue Pr > F
12.62 <.0001
0.1607
0.1480
Parameter Estimates
Variable Label
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
logincome_Kcapita
logphys_LMpop
pctO_14
pct65p
time
logprice_prod
log_numnew_compc
log_prod_detail_capit
generic
new
Intercept 1 46.19082
1 -2.54268
1 -4.18688
pct0_14 1 -62.82561
pct65p 1 -62.37477
Q1 1992 = 1 1 0.08235
1 0.27416
)und 1 -0.07332
a_lagl 1 0.06567
1 -1.12249
1 2.03498
127
95.63923
14.58026
12.03726
111.51595
62.66362
0.06794
0.12949
0.06080
0.01244
0.41273
0.33475
0.48
-0.17
-0.35
-0.56
-1.00
1.21
2.12
-1.21
5.28
-2.72
6.08
0.6293
0.8616
0.7281
0.5734
0.3199
0.2259
0.0346
0.2282
<.0001
0.0067
<.0001
With detailing variable lagged 4 quarters
Log-log regression for Antidepressants in Japan
Omitted drug type: branded; Omitted generation: old
The REG Procedure
Model: MODELi
Dependent Variable: log_prod_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Mean
Square F Value Pr > F
Model
Error
Corrected Total
10 443.74905
751 3318.01168
761 3761.76073
44.37490
4.41812
10.04 <.0001
Root MSE
Dependent Mean
Coeff Var
Parameter Estimates
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
log_income_lKcapi
log_physlMpop
pct0_14
pct65p
time
log_price_prod
log_num_new_com
log_proddetail_cai
generic
new
Intercept 1 32.61102
ta 1 -8.70892
1 -1.23863
pctO_14 1 -8.70359
pct65p 1 -56.87060
Q1 1992 = 1 1 0.10011
1 0.46164
pound 1 -0.07201
)ita_lag4 1 -0.03381
1 -0.98358
1 1.90762
2.10193
-11.69398
-17.97450
R-Square
Adj R-Sq
0.1180
0.1062
Variable Label
98.38110
13.69017
11.85028
97.53709
65.23434
0.07208
0.12195
0.05948
0.02241
0.46210
0.36046
0.33
-0.64
-0.10
-0.09
-0.87
1.39
3.79
-1.21
-1.51
-2.13
5.29
0.7404
0.5249
0.9168
0.9289
0.3836
0.1653
0.0002
0.2264
0.1317
0.0336
<.0001
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Appendix 5: SAS outputs of the regression results in
chapter 5
Table A5. 1 SAS output of Table 5.1
With detailing variable lagged 1 quarter
Linear regression for antihypertensives and antidepressants in Germany and Japan
Omitted country: Japan; Omitted therapeutic class: antidepressants
The REG Procedure
Model: MODEL1
Dependent Variable: tot_pd_capita
Analysis of Variance
Source
Sum of
DF Squares
Mean
Square FValue Pr > F
Model
Error
Corrected Total
11 0.00412
108 0.00006814
119 0.00418
0.00037415
6.309715E-7
592.98 <.0001
Root MSE
Dependent Mean
Coeff Var
0.00079434
0.00717
11.08097
R-Square 0.9837
Adj R-Sq 0.9821
Parameter Estimates
Label
Parameter Standard
DF Estimate Error tValue Pr > Itl
Intercept Intercept 1 0.02904
income_lKcapita 1 -0.00013132
phys_lMpop 1 -0.00001478
pctO_14 pctO_14 1 -0.03090
pct65p pct65p 1 -0.02017
time Q1 1992 = 1 1 0.00030254
price_class 1 -0.00737
price_ratio 1 0.00122
num_compound 1 -0.00001386
germany 1 0.02062
antihypertensives 1 0.01092
tot_detail_capita_lagl 1 158.11705
0.01948
0.00049715
0.00000227
0.06754
0.04333
0.00004586
0.00135
0.00014870
0.00002914
0.00306
0.00060154
47.54147
129
Variable
1.49
-0.26
-6.50
-0.46
-0.47
6.60
-5.45
8.21
-0.48
6.74
18.15
3.33
0.1389
0.7922
<.0001
0.6482
0.6426
<.0001
<.0001
<.0001
0.6352
<.0001
<.0001
0.0012
With detailing variable lagged 4 quarters
Linear regression for antihypertensives and antidepressants in Germany and Japan
Omitted country: Japan; Omitted therapeutic class: antidepressants
The REG Procedure
Model: MODEL1
Dependent Variable: totpd_capita
Analysis of Variance
Sum of Mean
Source DF Squares Square F Value Pr > F
Model
Error
Corrected Total
Root MSE
Dependent Mean
Coeff Var
11 0.00405 0.00036833 605.18
106 0.00006451 6.086311E-7
117 0.00412
0.00078015 R-Square 0.9843
0.00727 Adj R-Sq 0.9827
10.73663
Parameter Estimates
Parameter Standard
DF Estimate Error tValue Pr > Itl
Intercept
income_lKcapita
phys_lMpop
pct0_14
pct65p
time Q]
price_class
price_ratio
num_compound
germany
antihypertensives
tot_detail_capita_lj
Intercept 1 0.05418
1 -0.00092052 C
1 -0.00001129 C
pct0_14 1 -0.06916
pct65p 1 -0.06760
i 1992 = 1 1 0.00033842
1 -0.00867
1 0.00122
1 -0.00000416
1 0.01556
1 0.01052
ag4 1 41.92037
0.01859
).00049951
).00000296
0.06706
0.04141
0.00004309
0.00142
0.00014701
0.00002414
0.00395
0.00061140
10.40070
130
<.0001
Variable Label
2.91
-1.84
-3.82
-1.03
-1.63
7.85
-6.09
8.27
-0.17
3.94
17.21
4.03
0.0044
0.0681
0.0002
0.3047
0.1055
<.0001
<.0001
<.0001
0.8636
0.0001
<.0001
0.0001
___
Table A5. 2 SAS output of Table 5.2
With detailing variable lagged 1 quarter
Linear regression for antihypertensives and antidepressants in Germany and Japan
Omitted country: Japan; Omitted therapeutic class: antidepressants; Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: gen_pd_capita
Analysis of Variance
Source
Model
Error
Corrected Total
DF
15
280
295
Root MSE
Dependent Mean
Coeff Var
Sum of
Squares
0.00275
0.00029539
0.00305
0.00103
0.00291
35.28839
Mean
Square
0.00018347
0.00000105
F Value Pr > F
173.92 <.0001
R-Square 0.9031
Adj R-Sq 0.8979
Parameter Estimates
Variable Label
Parameter Standard
DF Estimate
Intercept Intercept 1 0.04326
income_lKcapita 1 -0.00127
phys_lMpop 1 0.00000142
pctO_14 pctO_14 1 -0.02176
pct65p pct65p 1 -0.09808
time Q1 1992 = 1 1 0.00015969
price_ratio 1 -0.00028275
price_gen 1 0.00515
num_new_compound 1 0.00013077
gen_detail_capita_lagl 1 -518.51748
new 1 -0.00895
middle 1 -0.01146
timenew 1 0.00004293
timemiddle 1 0.00018872
germany 1 -0.00141
antihypertensives 1 0.00690
Error tValue Pr > Itl
0.01505
0.00038784
0.00000193
0.05415
0.03133
0.00003681
0.00012657
0.00036235
0.00006633
33.33287
0.00064812
0.00081936
0.00001329
0.00002291
0.00256
0.00029524
131
2.87
-3.27
0.74
-0.40
-3.13
4.34
-2.23
14.22
1.97
-15.56
-13.81
-13.98
3.23
8.24
-0.55
23.37
0.0044
0.0012
0.4616
0.6880
0.0019
<.0001
0.0263
<.0001
0.0496
<.0001
<.0001
<.0001
0.0014
<.0001
0.5826
<.0001
With detailing variable lagged 4 quarters
Linear regression for antihypertensives and antidepressants in Germany and Japan
Omitted country: Japan; Omitted therapeutic class: antidepressants; Omitted generation: old
The REG Procedure
Model: MODEL1
Dependent Variable: gen_pd_capita
Analysis of Variance
Source
Model
Error
Corrected Total
DF
15
275
290
Root MSE
Dependent Mean
Coeff Var
Sum of
Squares
0.00257
0.00045433
0.00302
0.00129
0.00295
43.62366
Parameter Estimates
Variable Label
Mean
Square
0.00017127
0.00000165
F Value Pr > F
103.66 <.0001
R-Square 0.8497
Adj R-Sq 0.8415
Parameter Standard
DF Estimate
Intercept Intercept 1 0.04959
income_lKcapita 1 -0.00132
phys_lMpop 1 -0.00000116
pctO_14 pctO_14 1 -0.01508
pct65p pct65p 1 -0.11830
time Q1 1992 = 1 1 0.00020722
price_ratio 1 -0.00009245
price_gen 1 0.00593
num_new_compound 1 0.00018566
gendetailcapita_lag4 1 -142.41556
new 1 -0.01111
middle 1 -0.00742
timenew 1 0.00006270
timemiddle 1 0.00006674
germany 1 0.00165
antihypertensives 1 0.00747
Error t Value Pr > Itl
0.01936
0.00056118
0.00000316
0.06795
0.03987
0.00004657
0.00015738
0.00047632
0.00009292
18.94664
0.00083679
0.00094245
0.00001748
0.00002599
0.00427
0.00051063
132
2.56
-2.35
-0.37
-0.22
-2.97
4.45
-0.59
12.46
2.00
-7.52
-13.27
-7.87
3.59
2.57
0.39
14.63
0.0110
0.0195
0.7143
0.8245
0.0033
<.0001
0.5574
<.0001
0.0467
<.0001
<.0001
<.0001
0.0004
0.0108
0.7003
<.0001
1_1_1___
Table A5. 3 SAS output of Table 5.3
With detailing variable lagged 1 quarter
Linear regression for antihypertensives and antidepressants in Germany and Japan
Omitted country: Japan; Omitted therapeutic class: antidepressants
The REG Procedure
Model: MODEL1
Dependent Variable: share_new_pd
Analysis of Variance
Source
Model
Error
Corrected Total
Sum of
DF Squares
10 0.97374
106 0.06692
116 1.04066
Mean
Square
0.09737
0.00063133
F Value Pr > F
154.24 <.0001
Root MSE
Dependent Mean
Coeff Var
0.02513 R-Square 0.9357
0.11340 Adj R-Sq 0.9296
22.15708
Parameter Estimates
Label
Parameter Standard
DF Estimate Error tValue Pr > Itl
Intercept Ii
income_lKcapita
phys_lMpop
pct0_14
pct65p
ntercept
pct0_14
pct65p
time Q1 199;
price_ratio
share_num_newcmpnd
germany
antihypertensives
rel_detail_lagl
=1
1 -2.82432
1 0.00850
1 -0.00002504
1 10.18805
1 8.35483
1 0.00465
1 -0.03677
1 -0.66775
1 0.02085
1 -0.23859
1 -0.00568
Variable
0.61782
0.01485
0.00007373
2.25636
1.32883
0.00139
0.00483
0.13027
0.09658
0.01919
0.00220
-4.57
0.57
-0.34
4.52
6.29
3.35
-7.61
-5.13
0.22
-12.43
-2.58
<.0001
0.5681
0.7348
<.0001
<.0001
0.0011
<.0001
<.0001
0.8295
<.0001
0.0112
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With detailing variable lagged 4 quarters
Linear regression for antihypertensives and antidepressants in Germany and Japan
Omitted country: Japan; Omitted therapeutic class: antidepressants
The REG Procedure
Model: MODEL1
Dependent Variable: share_new_pd
Analysis of Variance
Source
Model
Error
Corrected Total
Sum of
DF Squares
10
104
114
0.96001
0.06527
1.02528
Mean
Square
0.09600
0.00062761
F Value Pr > F
152.96 <.0001
Root MSE
Dependent Mean
Coeff Var
0.02505
0.11491
21.80122
R-Square
Adj R-Sq
0.9363
0.9302
Parameter Estimates
Variable Label
Parameter Standard
DF Estimate Error
Intercept Intercept 1 -2.80119
income_lKcapita 1 -0.01661
phys_lMpop 1 0.00016500
pctO_14 pct0_14 1 10.92493
pct65p pct65p 1 8.66036
time Q1 1992 = 1 1 0.00431
price_ratio 1 -0.03278
share_num_newcmpnd 1 -0.48693
germany 1 -0.24349
antihypertensives 1 -0.20768
rel_detail_lag4 1 -0.00008993
0.63109
0.01798
0.00010137
2.20471
1.31232
0.00138
0.00474
0.12662
0.13383
0.01882
0.00066035
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t Value
-4.44
-0.92
1.63
4.96
6.60
3.12
-6.91
-3.85
-1.82
-11.03
-0.14
Pr > Itl
<.0001
0.3579
0.1066
<.0001
<.0001
0.0024
<.0001
0.0002
0.0717
<.0001
0.8919
Table A5. 4 SAS output of Table 5.4
With detailing variable lagged 1 quarter
Log-log regression for antihypertensives and antidepressants in Germany and Japan
Omitted country: Japan; Omitted therapeutic class: antidepressants;
Omitted generation: old; Omitted drug type: branded
The REG Procedure
Model: MODEL1
Dependent Variable: prod_pd_capita
Analysis of Variance
Source
Model
Error
Corrected Total
Root MSE
Dependent Mean
Coeff Var
DF
14
22002
22016
Sum of
Squares
0.00001727
0.00029094
0.00030820
0.00011499
0.00003875
296.75168
Mean
Square
0.00000123
1.322323E-8
FValue Pr > F
93.26 <.0001
R-Square 0.0560
Adj R-Sq 0.0554
Parameter Estimates
Parameter
Variable Label DF Estimate
Intercept Intercept 1 0.00034144
income_lKcapita 1 -0.00000749
phys_lMpop 1 -4.1024E-8
pctO 14 pctO _14 1 -0.00001795
pct65p pct65p 1 -0.00035030
time Q1 1992 = 1 1 5.119305E-7
priceprod 1 -1.52738E-7
num_new_compound 1 0.00000110
prod_detailcapita_lagl 1 55.74573
generic 1 -0.00001623
new 1 0.00001416
middle 1 2.091006E-7
oldgen 1 9.489773E-7
germany 1 0.00001332
antihypertensives 1 0.00003071
Standard
Error
0.00023118
0.00000523
2.328532E-8
0.00077898
0.00049078
4.457607E-7
5.508128E-8
8.265382E-7
3.35645
0.00000393
0.00000358
0.00000236
0.00000439
0.00003015
0.00000237
t Value
1.48
-1.43
-1.76
-0.02
-0.71
1.15
-2.77
1.34
16.61
-4.13
3.95
0.09
0.22
0.44
12.97
Pr > Itl
0.1397
0.1521
0.0781
0.9816
0.4754
0.2508
0.0056
0.1817
<.0001
<.0001
<.0001
0.9293
0.8289
0.6587
<.0001
13.5
With detailing variable lagged 4 quarters
Log-log regression for antihypertensives and antidepressants in Germany and Japan
Omitted country: Japan; Omitted therapeutic class: antidepressants;
Omitted generation: old; Omitted drug type: branded
The REG Procedure
Model: MODEL1
Dependent Variable: prod_pd_capita
Analysis of Variance
Sum of
Source DF Squares
Model 14 0.00001307
Error 29047 0.00031007
Corrected Total 29061 0.00032314
Root MSE
Dependent Mean
Coeff Var
0.00010332
0.00003227
320.17025
Mean
Square F Value Pr > F
9.335789E-7 87.46 <.0001
1.067481E-8
R-Square 0.0404
Adj R-Sq 0.0400
Parameter Estimates
Label
Parameter Standard
DF Estimate Error t Value Pr > Itl
Intercept
income_lKcapita
phys_lMpop
pctO_14
pct65p
time
price_prod
num_new_compc
prod_detail_capit
generic
new
middle
oldgen
germany
antihypertensives
Intercept 1 0.00049214
1 -0.00001143
1 2.452702E-9
pct0_14 1 -0.00067395
pct65p 1 -0.00061946
Q1 1992 = 1 1 5.2317E-7
1 -1.25321E-7
)und 1 5.029669E-7
a_lag4 1 10.48063
1 -0.00001668
1 0.00001287
1 0.00000567
1 0.00000393
1 -0.00003507
1 0.00002366
0.00019249
0.00000502
2.839996E-8
0.00062828
0.00040202
3.488127E-7
4.458483E-8
6.542198E-7
1.10081
0.00000326
0.00000258
0.00000192
0.00000363
0.00003682
0.00000186
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Variable
2.56
-2.28
0.09
-1.07
-1.54
1.50
-2.81
0.77
9.52
-5.11
4.98
2.95
1.08
-0.95
12.69
0.0106
0.0227
0.9312
0.2834
0.1234
0.1337
0.0049
0.4420
<.0001
<.0001
<.0001
0.0031
0.2787
0.3409
<.0001
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